<SEC-DOCUMENT>0001193125-12-151354.txt : 20120405
<SEC-HEADER>0001193125-12-151354.hdr.sgml : 20120405
<ACCEPTANCE-DATETIME>20120405115441
ACCESSION NUMBER:		0001193125-12-151354
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20120405
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120405
DATE AS OF CHANGE:		20120405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		12744490

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d329230d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): April&nbsp;5, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALENA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33958</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20-8099512</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission<BR>File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer<BR>Identification No.)</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon 97034 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (855)&nbsp;855-4253 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;5, 2011, Galena Biopharma, Inc. (&#147;<B>we</B>,&#148; &#147;<B>us</B>,&#148; &#147;<B>our</B>,&#148; &#147;<B>Galena</B>,&#148; or the &#147;<B>Company</B>&#148;) entered into an
underwriting agreement with Roth Capital Partners, LLC, as representative of the several underwriters named therein (the &#147;<B>Underwriter</B>s&#148;), relating to the public offering by us of 8,500,000 shares of our common stock, par value
$0.0001 per share. The shares are being sold at a public offering price of $1.50 per share. The Underwriters will purchase the shares at a discounted price of $1.395 per share, representing a 7% discount from the public offering price. We have
granted the Underwriters an option for a period of 30&nbsp;days from the date of the underwriting agreement to purchase up to an additional 1,275,000 shares of common stock from us to cover overallotments, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering is expected to close on April&nbsp;11, 2012, subject to the satisfaction of customary closing conditions. The net proceeds
to us are expected to be approximately $11.6 million, assuming no exercise of the Underwriters&#146; over-allotment option and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the Underwriters
exercise the over-allotment option in full, the total net proceeds to us of the offering, after deducting underwriting discounts and commissions and offering expenses, are expected to be $13.4 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering is being made pursuant to our existing shelf registration statement on Form S-3 (File No.&nbsp;333-167025), which was filed
with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) on May&nbsp;21, 2010 and declared effective by the Commission on May&nbsp;28, 2010, and is described in more detail in a prospectus supplement dated April&nbsp;5, 2012
and an accompanying base prospectus dated May&nbsp;21, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement contains customary representations,
warranties, and agreements by us, and customary conditions to closing, indemnification obligations of us and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination
provisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement is included as an exhibit to this Current Report to provide investors and security
holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the underwriting agreement were made only for purposes of such
agreement and as of specific dates, were solely for the benefit of the parties to the underwriting agreement, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures exchanged between the
parties in connection with the execution of the underwriting agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the opinion of TroyGould PC relating to the
legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto. A copy of the underwriting agreement is filed herewith as Exhibit&nbsp;1.1 and is incorporated herein by reference. The foregoing description of the
offering and the underwriting agreement do not purport to be complete and is qualified in its entirety by reference to such Exhibits. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Reference is made to the description of the offering in Item&nbsp;1.01. We agreed in the underwriting agreement, subject to certain exceptions, not to offer and sell any shares of our common stock or
securities convertible into or exercisable or exchangeable for shares of our common stock at an effective price per share less than the public offering price per share in the offering for a period of thirty (30)&nbsp;days following the offering,
without the written consent of the representative. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;4, 2012 and April&nbsp;5, 2012, respectively, we issued
press releases announcing the offering and the pricing of the offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are filing as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein
by reference. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: April&nbsp;5, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Index to Exhibits </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting Agreement dated as of April&nbsp;5, 2012 by and between Galena Biopharma, Inc. and Roth Capital Partners, LLC, as representative of the several underwriters named
therein</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of TroyGould PC</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of TroyGould PC (contained in Exhibit 5.1 above)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release of Galena Biopharma, Inc. issued April&nbsp;4, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release of Galena Biopharma, Inc. issued April&nbsp;5, 2012</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d329230dex11.htm
<DESCRIPTION>UNDERWRITING AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Underwriting Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 1.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>8,500,000 Shares of Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNDERWRITING AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;5, 2012 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roth Capital Partners, LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">888 San Clemente Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Newport Beach, CA 92660
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>As Representative of the Underwriters </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>named on Schedule I hereto </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Sirs: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <I>I<SMALL>NTRODUCTION</SMALL></I><SMALL></SMALL>. Galena Biopharma, Inc. (f/k/a RXi Pharmaceuticals Corporation), a Delaware
corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the underwriters named in Schedule I hereto (the &#147;<B>Underwriters</B>&#148;) for whom Roth Capital Partners, LLC is acting as representative (the
&#147;<B>Representative</B>&#148;), pursuant to the terms and conditions of this Underwriting Agreement (this &#147;<B>Agreement</B>&#148;), an aggregate of 8,500,000 shares of common stock, $0.0001 par value per share (the &#147;<B>Common
Stock</B>&#148;) of the Company (the &#147;<B>Firm Shares</B>&#148;). The proposed offering, issuance and sale of the Firm Shares are hereby referred to as the &#147;<B>Offering</B>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has granted the Underwriters the option (the &#147;<B>Overallotment Option</B>&#148;) to purchase an aggregate of up to
1,275,000 additional shares of Common Stock (the &#147;<B>Option Shares</B>&#148;). The Firm Shares and the Option Shares are collectively referred to as the &#147;<B>Shares</B>.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <I>D<SMALL>ELIVERY</SMALL> <SMALL>AND</SMALL> P<SMALL>AYMENT</SMALL></I><SMALL></SMALL>. On the basis of the representations,
warranties and agreements of the Company herein contained, and subject to the terms and conditions of this Agreement: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 The Company agrees to issue and sell and each Underwriter agrees, severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite such
Underwriter&#146;s name on <U>Schedule I</U> hereto at a purchase price of $1.395 per Firm Share (the &#147;<B>Purchase Price</B>&#148;). The Company has been advised by you that you propose to make a public offering of the Firm Shares as soon after
this Agreement has become effective as in your judgment is advisable. The Company is further advised by you that the Units are to be offered to the public initially at a price of $1.50 per Firm Share (the &#147;<B>Public Offering Price</B>&#148;).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 The Company hereby grants to the Underwriters the option to purchase some or all of the Option Shares
and, upon the basis of the warranties and representations and subject to the terms and conditions herein set forth, the Underwriters shall have the right to purchase all or any portion of the Option Shares at the Purchase Price as may be necessary
to cover over-allotments made in connection with the transactions contemplated hereby. This option may be exercised by the Representative at any time </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and from time to time on or before the thirtieth (30th)&nbsp;day following the date hereof, by written notice to the Company (the &#147;<B>Option Notice</B>&#148;). The Option Notice shall set
forth the aggregate number of Option Shares as to which the option is being exercised, and the date and time when the Option Shares are to be delivered (such date and time being herein referred to as an &#147;<B>Option Closing Date</B>&#148;);
provided, however, that the Option Closing Date shall not be earlier than the Closing Date (as defined below) nor earlier than the first business day after the date on which the option shall have been exercised nor later than the fifth business day
after the date on which the option shall have been exercised unless the Company and the Underwriters otherwise agree. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Payment of the purchase price for and delivery of the Option Shares shall be made on an Option Closing Date in the same manner and at the same office as the payment for the Firm Shares as set forth in
<U>Section&nbsp;2.3</U> below. For the purpose of expediting the checking of the certificate for the Option Shares by the Underwriters, the Company agrees to make a form of such certificate available to the Underwriters for such purpose at least one
full business day preceding an Option Closing Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 Payment of the Purchase Price for, and delivery of,
the Firm Shares shall be made at the time and date of closing and delivery of the documents required to be delivered to the Underwriters pursuant to <U>Sections 4</U> and <U>6</U> hereof, which shall be at 11:00 A.M., New York time, on
April&nbsp;11, 2012 (the &#147;<B>Closing Date</B>&#148;) at the offices of Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660 or at such other time and date as the Representative and the Company determine pursuant
to Rule 15c6-1(a) under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), or, in the case of the Option Shares, at such date and time set forth in the Option Notice. Delivery of the Shares shall be made by credit
through full fast transfer to the account of the Depository Trust Company designated by the Representative. Certificates representing the Shares, in definitive form and in such denominations and registered in such names as the Underwriters may
request upon at least two business days&#146; prior notice to the Company, will be made available for checking and packaging not later than 10:30 a.m. PDT on the business day next preceding the Closing Date at the above addresses, or such other
location as may be mutually acceptable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 No Shares which the Company has agreed to sell pursuant to this
Agreement shall be deemed to have been purchased and paid for, or sold by the Company, until the Shares shall have been delivered to the Underwriters against payment by the Underwriters. If the Company shall default in its obligations to deliver any
Shares to the Underwriters, the Company shall indemnify and hold the Underwriters harmless against any loss, claim, damage or expense arising from or as a result of such default by the Company in accordance with the procedures set forth in
<U>Section&nbsp;7(c)</U> herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <I>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></I><SMALL></SMALL>. The Company represents and warrants to the Underwriters and agrees with the Underwriters that: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the
&#147;<B>Securities Act</B>&#148;), and published rules and </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulations thereunder (the &#147;<B>Rules and Regulations</B>&#148;) adopted by the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a &#147;shelf&#148; Registration
Statement (as hereinafter defined) on Form S-3 (File No.&nbsp;333-167025), which became effective as of May&nbsp;28, 2010 (the &#147;<B>Effective Date</B>&#148;), including a base prospectus relating to the Shares (the &#147;<B>Base
Prospectus</B>&#148;), and such amendments and supplements thereto as may have been required to the date of this Agreement. The term &#147;<B>Registration Statement</B>&#148; as used in this Agreement means the registration statement (including all
exhibits, financial schedules and all documents and information deemed to be a part of the Registration Statement pursuant to Rule 430A of the Rules and Regulations), as amended and/or supplemented to the date of this Agreement, including the Base
Prospectus. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus (as defined below) has been
issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the Rules and Regulations of the Commission, will file the
Prospectus (as defined below) with the Commission pursuant to Rule 424(b) of the Rules and Regulations. The term &#147;<B>Prospectus</B>&#148; as used in this Agreement means the Base Prospectus and the prospectus supplement relating to the offering
of the Shares, in the form in which it is to be filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations, except that if any revised prospectus or prospectus supplement shall be provided to the Underwriters by the Company for
use in connection with the Offering which differs from the Prospectus (whether or not such revised prospectus or prospectus supplement is required to be filed by the Company pursuant to Rule 424(b) of the Rules and Regulations), the term
&#147;<B>Prospectus</B>&#148; shall refer to the Prospectus as so revised by such prospectus or prospectus supplement, as the case may be, from and after the time it is first provided to the Underwriters for such use (or in the form first made
available to the Underwriters by the Company to meet requests of prospective purchasers pursuant to Rule 173 under the Securities Act). Any preliminary prospectus or prospectus subject to completion included in the Registration Statement or filed
with the Commission pursuant to Rule 424 of the Rules and Regulations is hereafter called a &#147;<B>Preliminary Prospectus</B>.&#148; Any reference herein to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed
to refer to and include the documents incorporated by reference therein pursuant to Item&nbsp;12 of Form S-3 which were filed under the Exchange Act, on or before the last to occur of the Effective Date, the date of the Preliminary Prospectus, or
the date of the Prospectus, and any reference herein to the terms &#147;amend,&#148; &#147;amendment,&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer
to and include (i)&nbsp;the filing of any document under the Exchange Act after the Effective Date, the date of such Preliminary Prospectus or the date of the Prospectus, as the case may be, which is incorporated by reference and (ii)&nbsp;any such
document so filed. If the Company has filed an abbreviated registration statement to register additional securities pursuant to Rule 462(b) under the Rules and Regulations (the &#147;<B>462(b) Registration Statement</B>&#148;), then any reference
herein to the Registration Statement shall also be deemed to include such 462(b) Registration Statement. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) As of the Applicable Time (as defined below), as of the Closing Date and
as of any Option Closing Date, neither (i)&nbsp;any General Use Free Writing Prospectus (as defined below) issued at or prior to the Applicable Time, and the Pricing Prospectus (as defined below), all considered together (collectively, the
&#147;<B>General Disclosure Package</B>&#148;), (ii)&nbsp;any individual Limited Use Free Writing Prospectus (as defined below) issued at or prior to the Applicable Time, nor (iii)&nbsp;the bona fide electronic road show (as defined in Rule
433(h)(5) of the Rules and Regulations), if any, that has been made available without restriction to any person, when considered together with the General Disclosure Package, included or will include, any untrue statement of a material fact or
omitted or as of the Closing Date or any Option Closing Date will omit, to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided,
however</I>, that the Company makes no representations or warranties as to information contained in or omitted from any Issuer Free Writing Prospectus or the Pricing Prospectus, in reliance upon, and in conformity with, written information furnished
to the Company by the Underwriters specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>). As used in this <U>paragraph (b)</U>&nbsp;and
elsewhere in this Agreement: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Applicable Time</I></B>&#148; means 8:00 A.M., New York time, on the date of this
Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>General Use Free Writing Prospectus</I></B>&#148; means any Issuer Free Writing Prospectus that is
identified on <U>Schedule A</U> to this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Issuer Free Writing Prospectus</I></B>&#148; means any
&#147;<B>issuer free writing prospectus,</B>&#148; as defined in Rule 433 of the Rules and Regulations relating to the Shares in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the
Company&#146;s records pursuant to Rule 433(g) of the Rules and Regulations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Limited Use Free Writing
Prospectuses</I></B>&#148; means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>Pricing Prospectus</I></B>&#148; means the Preliminary Prospectus, if any, and the Base Prospectus, each as amended and
supplemented immediately prior to the Applicable Time, including any document incorporated by reference therein, any Issuer Free Writing Prospectus and any prospectus supplement deemed to be a part thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) No order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the
Prospectus relating to the Offering has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act has been instituted or, to the knowledge of the Company, threatened by the Commission, and
any Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities Act and the Rules and Regulations, and, unless otherwise corrected, modified or supplemented, did not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided, however</I>,
that the </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company makes no representations or warranties as to information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in conformity with, written information furnished
to the Company by the Underwriters specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) At the respective times the Registration Statement and any amendments thereto became or become effective, at the date
of this Agreement, at the Closing Date and at any Option Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and Regulations
and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or
supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued, at the Closing Date and at any Option Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and
the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading; <I>provided, however</I>, that the foregoing representations and warranties in this <U>paragraph (d)</U>&nbsp;shall not apply to information contained in or omitted from the Registration Statement or the Prospectus, or any amendment or
supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company by the Underwriters specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146;
Information (as defined in <U>Section&nbsp;18</U>). The Prospectus contains all required information under the Securities Act with respect to the Shares and the distribution thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent times through the completion
of the Offering or until any earlier date that the Company notified or notifies the Underwriters as described in <U>Section&nbsp;4(e)</U>, did not, does not and will not include any information that materially conflicted, conflicts or will conflict
with the information contained in the Registration Statement, Pricing Prospectus or the Prospectus, including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof that has not been superseded or
modified, or includes an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company by the Underwriters
specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) The documents incorporated by reference in the Prospectus, when they became effective or were filed with the
Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
applicable, and the rules and regulations of the Commission thereunder and none of such documents contained any untrue statement of a material fact or omitted to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Prospectus, when such documents
become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and
will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) At the time of filing the Registration Statement, any 462(b) Registration Statement and any
post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an &#147;ineligible issuer,&#148; as defined in Rule 405 of the Rules and Regulations. The Company has not, directly or indirectly,
distributed and will not distribute any offering material in connection with the Offering other than any Preliminary Prospectus, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with
<U>Section&nbsp;</U>4(b) below. The Company will file with the Commission all Issuer Free Writing Prospectuses (other than a &#147;road show,&#148; as described in Rule 433(d)(8) of the Rules and Regulations), if any, in the time and manner required
under Rules 163(b)(2) and 433(d) of the Rules and Regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) The Company and each Subsidiary (as
defined below) has been duly organized and is validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Company and each Subsidiary is duly qualified to do business and is in good standing as
foreign corporation in each jurisdiction in which its ownership or lease of property or the conduct of its business require such qualification and has all power and authority necessary to own or hold its properties and to conduct the business in
which it is engaged, except where the failure to so qualify or have such power or authority would not (i)&nbsp;have, singly or in the aggregate, a material adverse effect on the condition (financial or otherwise), results of operations, assets,
business or prospects of the Company and its Subsidiaries, taken as a whole, or (ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by
this Agreement, the General Disclosure Package or the Prospectus (any such effect as described in clauses (i)&nbsp;or (ii), a &#147;Material Adverse Effect&#148;). The Company owns or controls, directly or indirectly, only the following
corporations, partnerships, limited liability partnerships, limited liability companies, associations or other entities: Apthera, Inc. and RXi Pharmaceuticals Corporation (&#147;RXi&#148;) (each, a &#147;Subsidiary&#148;). The Board of Directors of
the Company has approved the proposed distribution (the &#147;Distribution&#148;) of 47,341,594 shares of common stock of RXi (constituting approximately 8% of RXi&#146;s fully diluted common stock) to the Company&#146;s stockholders and, to effect
the Distribution has declared a conditional dividend on the Common Stock of one share of RXi common stock for each outstanding share of Common Stock to holders of record of the Common Stock as of March&nbsp;8, 2012 (the &#147;Distribution
Dividend&#148;). The Distribution has been registered by RXi pursuant to a registration statement on Form S-1 (file no. 333-177498) (the &#147;RXi </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<B>Registration Statement</B>&#148;) which was declared effective by the Commission on February&nbsp;12, 2012. For the avoidance of doubt, RXi shall be deemed to be a &#147;Subsidiary&#148; of
the Company for purposes of this Agreement notwithstanding the Distribution Dividend. At the time the RXi Registration Statement became effective, at the date of this Agreement, at the Closing Date and at any Option Closing Date, the RXi
Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and any prospectus included in
the RXi Registration Statement, at the time such prospectus or any amendment or supplement thereto was issued, at the Closing Date and at any Option Closing Date, did not and will not contain an untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) The Company has the full right, power and authority to enter into this Agreement and to perform and to discharge its obligations hereunder; and this Agreement has been duly authorized, executed and
delivered by the Company, and constitutes a valid and binding obligation of the Company enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors&#146; and contracting parties&#146; rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law)
and except as to the enforceability of any rights to indemnification or contribution that may be violative of the public policy underlying any law, rule or regulation (including any federal or state securities law, rule or regulation). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) The Shares to be issued and sold by the Company to the Underwriters hereunder have been duly and validly authorized
and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and nonassessable and free of any preemptive or similar rights and will conform to the description thereof contained in the
Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) The Company has an authorized
capitalization as set forth in the General Disclosure Package, and all of the issued and outstanding shares of capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable, have been issued in
compliance with federal and state securities laws, and conform to the description thereof contained in the General Disclosure Package and the Prospectus. As of March&nbsp;26, 2012, there were 50,493,396 shares of Common Stock issued and outstanding
and no shares of Preferred Stock, par value $0.0001 of the Company issued and outstanding, and 20,588,835 shares of Common Stock were issuable upon the exercise of all options, warrants and convertible securities outstanding as of such date. Since
such date, the Company has not issued any securities, other than Excluded Issuances (as defined below). All of the Company&#146;s stock options, warrants and other rights to purchase or exchange any securities for shares of the Company&#146;s
capital stock have been duly authorized and validly issued and were issued in compliance with U.S. federal and state securities laws. The Shares to be issued and sold by the Company under this Agreement will conform to the description thereof in the
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Registration Statement, the General Disclosure Package and the Prospectus in all material respects; and no person or entity has the right to require registration of shares of Common Stock or
other securities of the Company because of the filing or effectiveness of the Registration Statement and the Shares will be free of statutory and contractual preemptive rights, resale rights, rights of first refusal and similar rights, other than as
described in the Registration Statement, the General Disclosure Package and the Prospectus. None of the outstanding shares of Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase securities of the Company. There are no authorized or outstanding shares of capital stock, stock options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into
or exchangeable or exercisable for, any capital stock of the Company other than those described above or accurately described in the Registration Statement, the General Disclosure Package and the Prospectus. The description of the Company&#146;s
stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as described in the Registration Statement, the General Disclosure Package and the Prospectus, accurately and fairly present the
information required to be shown with respect to such plans, arrangements, options and rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) All the
outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued, are fully paid and non-assessable and, except for the Distribution as described in the Registration Statement, the General Disclosure Package and
the Prospectus, are owned by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear of any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third
party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) The execution, delivery and performance of this Agreement, the issuance and sale of the Shares by
the Company and the consummation of the transactions contemplated hereby and thereby will not (with or without notice or lapse of time or both) (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of,
constitute a default or Debt Repayment Triggering Event (as defined below) under, give rise to any right of termination or other right or the cancellation or acceleration of any right or obligation or loss of a benefit under, or give rise to the
creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property or assets of the Company or any Subsidiary pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or to which any of the property or assets of the Company or any Subsidiary is subject, (ii)&nbsp;result in any violation of the provisions of the
charter or by-laws (or analogous governing instruments, as applicable) of the Company or any Subsidiary or (iii)&nbsp;result in any violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or any Subsidiary or any of their properties or assets, except, with respect to clauses (i)&nbsp;and (iii), for such conflicts, breaches or violations as would not, singly or in the
aggregate, result in a Material Adverse Effect. A &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note, debenture or other
evidence of indebtedness (or any </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any Subsidiary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) Except for (i)&nbsp;the registration of the Shares under the Securities Act, and (ii)&nbsp;such consents, approvals,
authorizations, registrations or qualifications as may be required under the Exchange Act and applicable state or foreign securities laws, the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) and the Nasdaq Capital Market
(&#147;<B>Nasdaq CM</B>&#148;) in connection with the Offering, no consent, approval, authorization or order of, or filing, qualification or registration with, any court or governmental agency or body, foreign or domestic, which has not been made,
obtained or taken and is not in full force and effect, is required for the execution, delivery and performance of this Agreement by the Company, the Offering or the consummation of the transactions contemplated hereby. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) To the Company&#146;s knowledge, BDO USA, LLP, who have audited certain financial statements and related schedules of
the Company included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, is an independent registered public accounting firm with respect to the Company as required by the Securities Act and
the Rules and Regulations and the Public Company Accounting Oversight Board (United States) (the &#147;<B>PCAOB</B>&#148;). Except as pre-approved in accordance with the requirements set forth in Section&nbsp;10A of the Exchange Act, BDO USA, LLP
has not been engaged by the Company to perform any &#147;prohibited activities&#148; (as defined in Section&nbsp;10A of the Exchange Act). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(p) The financial statements of the Company, together with the related notes and schedules, included or incorporated by reference in the General Disclosure Package, the Prospectus and in the Registration
Statement fairly present the financial position and the results of operations and changes in financial position of the Company and its consolidated Subsidiaries at the respective dates or for the respective periods therein specified. Such statements
and related notes and schedules have been prepared in accordance with the generally accepted accounting principles in the United States (&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved except as may be set
forth in the related notes included or incorporated by reference in the General Disclosure Package. Such financial statements, together with the related notes and schedules, included or incorporated by reference in the Registration Statement, the
General Disclosure Package and the Prospectus comply in all material respects with the Securities Act, the Exchange Act, and the Rules and Regulations and the rules and regulations under the Exchange Act. No other financial statements or supporting
schedules or exhibits with respect to the Company are required by the Securities Act or the Rules and Regulations to be described, or included or incorporated by reference in the Registration Statement, the General Disclosure Package or the
Prospectus. There is no pro forma or as adjusted financial information which is required to be included in the Registration Statement, the General Disclosure Package, or the Prospectus or a document incorporated by reference therein in accordance
with the Securities Act and the Rules and Regulations which has not been included or incorporated as so required. The pro forma and pro forma as adjusted financial information and the related notes included or incorporated by reference in the
Registration Statement, the General Disclosure Package </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the Rules and Regulations and present fairly the information
shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) Neither the Company nor any Subsidiary has sustained, since the date of the latest audited financial statements
included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Registration Statement, the General Disclosure Package and the Prospectus; and, since such date, except as
described in the Registration Statement, the General Disclosure Package and the Prospectus, there has not been any change in the capital stock (other than Common Stock issued pursuant to (i)&nbsp;the exercise of stock options, or the grant of
restricted stock awards, pursuant to the Company&#146;s stock incentive plans and (ii)&nbsp;the exercise of warrants issued by the Company) (collectively, the &#147;<B>Excluded Issuances</B>&#148;) or long-term debt of the Company or any Subsidiary,
or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, assets, general affairs, management, financial position, prospects, stockholders&#146; equity or results of operations
of the Company or any Subsidiary, otherwise than, in each case, as set forth or contemplated in the Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(r) Except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, there is no
legal or governmental action, suit, claim or proceeding pending to which the Company or any Subsidiary is a party or of which any property or assets of the Company or any Subsidiary is the subject which is required to be described in the
Registration Statement, the General Disclosure Package or the Prospectus or a document incorporated by reference therein and is not described therein, or which, singularly or in the aggregate, if determined adversely to the Company or any Subsidiary
would reasonably be expected to have a Material Adverse Effect or prevent the consummation of the transactions contemplated hereby; and to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities
or threatened by others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(s) Neither the Company nor any Subsidiary is in (i)&nbsp;violation of its charter
or by-laws (or analogous governing instrument, as applicable), (ii)&nbsp;default in any respect, and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject or
(iii)&nbsp;violation in any respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which it or its property or assets may be subject except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;of this
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
paragraph (s), for any violations or defaults which, singly or in the aggregate, would not have a Material Adverse Effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(t) The pre-clinical studies conducted by or on behalf of or sponsored by the Company or any Subsidiary that are
described in the Registration Statement, the General Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being
conducted in all material respects in accordance with scientific research procedures that the Company reasonably believes are appropriate. The descriptions in the Registration Statement, the General Disclosure Package and the Prospectus of the
results of such studies are accurate in all material respects and fairly present the data derived from such studies, and the Company has no knowledge of any studies or tests performed by or on behalf of the Company or any Subsidiary the results of
which are materially inconsistent with or otherwise materially call into question the results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(u) The Company and each Subsidiary possesses all licenses, certificates, authorizations and permits issued by, and has
made all declarations and filings with, the appropriate local, state, federal or foreign regulatory agencies or bodies which are necessary for the ownership of its properties or the conduct of its business as currently conducted or as described in
the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the &#147;<B>Governmental Permits</B>&#148;), except where any failures to possess or make the same, singly or in the aggregate, would not have a Material
Adverse Effect. The Company and each Subsidiary is in compliance with all such Governmental Permits and all such Governmental Permits are valid and in full force and effect, except where the non-compliance, invalidity or failure to be in full force
and effect would not, singly or in the aggregate, have a Material Adverse Effect. All such Governmental Permits are free and clear of any restriction or condition that are in addition to, or materially different from those normally applicable to
similar licenses, certificates, authorizations and permits, except for such restrictions, conditions or differences which would not, singly or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary has received
notification of any revocation or modification (or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental Permit will not be renewed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Neither the Company nor any Subsidiary is and, after giving effect to the Offering and the application of the
proceeds thereof as described in the Registration Statement, the General Disclosure Package and the Prospectus, will not become an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and
regulations of the Commission thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(w) Neither the Company nor any Subsidiary, nor to the
Company&#146;s knowledge, any of the Company&#146;s or any Subsidiary&#146;s officers, directors or affiliates has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of
the Company, or which caused or resulted in, or </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x) The Company and each Subsidiary owns or possesses the right to use all material patents, trademarks, trademark
registrations, service marks, service mark registrations, trade names, copyrights, licenses, inventions, software, databases, know-how, Internet domain names, trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures, and other intellectual property (collectively, &#147;<B>Intellectual Property</B>&#148;) necessary to carry on their respective businesses as currently conducted or as described in the Registration Statement, the
General Disclosure Package and the Prospectus, and the Company is not aware of any claim to the contrary or any challenge by any other person to the rights of the Company or any Subsidiary with respect to the foregoing except for those that would
not reasonably be expected to have a Material Adverse Effect. The Intellectual Property licenses described in the Registration Statement, the General Disclosure Package and the Prospectus are valid, binding upon, and enforceable by or against the
parties thereto in accordance to their terms. The Company and each Subsidiary has complied in all material respects with, and is not in breach of, nor has it received any asserted or threatened claim of breach of, any Intellectual Property license,
and the Company has no knowledge of any breach or anticipated breach by any other person to any such Intellectual Property license. The Company&#146;s and each Subsidiary&#146;s business as now conducted and as proposed to be conducted does not and
will not infringe or conflict with any valid patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses or other Intellectual Property or franchise right of any person. Except as disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, the Company has not received notice that any claim has been made against the Company or any Subsidiary alleging the infringement by the Company or any Subsidiary of any patent, trademark, service mark,
trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person. The Company and each Subsidiary has taken all reasonable steps to protect, maintain and safeguard its rights in all Intellectual
Property, including the execution of appropriate nondisclosure and confidentiality agreements. The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with
respect to, nor require the consent of any other person in respect of, each of the Company&#146;s and each Subsidiary&#146;s right to own, use, or hold for use any of the Intellectual Property as owned, used or held for use in the conduct of its
business as currently conducted. With respect to the use of software developed by the Company or any Subsidiary in the business of the Company or any Subsidiary as it is currently conducted, neither the Company nor any Subsidiary has experienced any
material defects in such software other than defects which have been or will be corrected, and no such software contains any device or feature designed to disrupt, disable, or otherwise impair the functioning of any software or is subject to the
terms of any &#147;open source&#148; or other similar license that provides for the source code of the software to be publicly distributed or dedicated to the public. The Company and each Subsidiary has at all times complied with all applicable laws
relating to privacy, data protection, and the collection and use of personal information collected, used, or held for use by the Company or any Subsidiary in the conduct of the Company&#146;s or any Subsidiary&#146;s
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
business. The Company has received no notice of any claims asserted or threatened against the Company or any Subsidiary alleging a violation of any law related to privacy, data protection, or the
collection and use of personal information collected, used, or held for use by the Company or any Subsidiary in the conduct of the Company&#146;s or any Subsidiary&#146;s business. The Company and each Subsidiary takes reasonable measures to ensure
that such information is protected against unauthorized access, use, modification, or other misuse. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(y) The
Company and each Subsidiary has good and marketable title in fee simple to, or has valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and any Subsidiary as currently
conducted, in each case free and clear of all liens, encumbrances, security interests, claims and defects, other than those that do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company or any Subsidiary; and all of the leases and subleases material to the business of the Company or any Subsidiary, and under which the Company or any Subsidiary holds properties described in the
Registration Statement, the General Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material claim of any sort that has been asserted by anyone adverse to
the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or any Subsidiary to the continued possession of the leased or subleased premises under any such
lease or sublease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(z) No labor disturbance by the employees of the Company or any Subsidiary exists or, to
the Company&#146;s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any Subsidiary&#146;s principal suppliers, manufacturers, customers or contractors, that would
reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company or any Subsidiary plans to terminate employment with the
Company or any Subsidiary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(aa) No &#147;prohibited transaction&#148; (as defined in Section&nbsp;406 of the
Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<B>ERISA</B>&#148;), or Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended from time to time (the
&#147;<B>Code</B>&#148;)) or &#147;accumulated funding deficiency&#148; (as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043(b) of ERISA (other than events with respect to which the thirty (30)-day notice
requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or would reasonably be expected to occur with respect to any employee benefit plan of the Company or any Subsidiary which would, singly or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Each employee benefit plan of the Company or any Subsidiary is in compliance in all material respects with applicable law, including ERISA and the Code. The Company and each Subsidiary has not incurred and
would not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pension plan for which the Company or any Subsidiary would have any liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred,
whether by action or by failure to act, which would, singly or in the aggregate, reasonably be expected to cause the loss of such qualification. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(bb) The Company and each Subsidiary is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic
substances or waste and protection of health and safety or the environment which are applicable to its business (&#147;<B>Environmental Laws</B>&#148;), except where the failure to comply would not, singularly or in the aggregate, have a Material
Adverse Effect. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company or
any Subsidiary (or, to the Company&#146;s knowledge, any other entity for whose acts or omissions the Company or any Subsidiary is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or any
Subsidiary, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order,
judgment, decree or permit, give rise to any liability, except for any violation or liability which would not have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse Effect; and there has been no disposal,
discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge, except for any such
disposal, discharge, emission, or other release of any kind which would not have, singularly or in the aggregate with all such discharges and other releases, a Material Adverse Effect. In the ordinary course of business, the Company conducts
periodic reviews of the effect of Environmental Laws on its business and assets, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for
clean-up, closure of properties or compliance with Environmental Laws or Governmental Permits issued thereunder, any related constraints on operating activities and any potential liabilities to third parties). On the basis of such reviews, the
Company has reasonably concluded that such associated costs and liabilities would not have, singularly or in the aggregate, a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(cc) The Company and each Subsidiary (i)&nbsp;has timely filed or been granted extensions for all necessary federal, state, local and foreign tax returns, and all such returns were true, complete and
correct, (ii)&nbsp;has paid all federal, state, local and foreign taxes, assessments, governmental or other charges due and payable for which it is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any
Subsidiary is obligated to withhold from amounts owing to employees, creditors and third parties, and (iii)&nbsp;does not have any tax deficiency or claims outstanding or assessed or, to the best of its knowledge, proposed against any of them,
except those, in each of the cases described in clauses (i), (ii)&nbsp;and (iii)&nbsp;of this paragraph (cc), that would not, singularly or in the aggregate, have a Material Adverse Effect. The Company and each Subsidiary has not engaged in any
transaction which is a corporate tax shelter or which </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
could be characterized as such by the Internal Revenue Service or any other taxing authority. The accruals and reserves on the books and records of the Company and each Subsidiary in respect of
tax liabilities for any taxable period not yet finally determined are adequate to meet any assessments and related liabilities for any such period, and since December&nbsp;31, 2011 neither Company nor any Subsidiary has incurred any liability for
taxes other than in the ordinary course. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(dd) The Company and each Subsidiary carries, or is covered by,
insurance provided by recognized, financially sound and reputable institutions with policies in such amounts and covering such risks as the Company deems adequate for the conduct of the business of the Company or any Subsidiary and the value of
their respective properties and as is customary for companies engaged in similar businesses in similar industries. The Company has no reason to believe that it or any Subsidiary will not be able (i)&nbsp;to renew its existing insurance coverage as
and when such coverage expires or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary to conduct their respective businesses as now conducted and at a cost that would not result in a Material Adverse Effect. Neither
the Company nor any Subsidiary has been denied any insurance coverage that it has sought or for which it has applied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ee) The Company and each Subsidiary maintains a system of internal accounting and other controls sufficient to provide reasonable assurances that (i)&nbsp;transactions are executed in accordance with
management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is
permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (A)&nbsp;no material weakness in the
Company&#146;s internal control over financial reporting (whether or not remediated) and (B)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company&#146;s internal control over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ff) The minute books of the Company and each
Subsidiary have been made available to the Underwriters and counsel for the Underwriters, and such books (i)&nbsp;contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders of
the Company and each Subsidiary (or analogous governing bodies and interest holders, as applicable) since the time of its respective incorporation or organization through the date of the latest meeting and action, and (ii)&nbsp;accurately in all
material respects reflect all actions referred to in such minutes or written consents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(gg) To the
Company&#146;s knowledge, there is no franchise, lease, contract, agreement or document required by the Securities Act or by the Rules and Regulations to be described in the Registration Statement, the General Disclosure Package and the Prospectus
or a document incorporated by reference therein or to be filed as an exhibit to </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Registration Statement or a document incorporated by reference therein which is not described or filed therein as required; and all descriptions of any such franchises, leases, contracts,
agreements or documents contained in the Registration Statement, the General Disclosure Package, the Prospectus or in any document incorporated by reference therein are accurate and complete descriptions of such documents in all material respects.
Other than as described in the Registration Statement, the General Disclosure Package and the Prospectus, no such franchise, lease, contract or agreement has been suspended or terminated for convenience or default by the Company or any Subsidiary or
any of the other parties thereto, and neither the Company nor any Subsidiary has received notice nor does the Company have any other knowledge of any such pending or threatened suspension, termination or non-renewal, except for such pending or
threatened suspensions, terminations or non-renewals that would not reasonably be expected to, singly or in the aggregate, have a Material Adverse Effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(hh) No relationship, direct or indirect, exists between or among the Company or any Subsidiary on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or
suppliers of the Company or any Subsidiary or any of their affiliates on the other hand that is required to be described in the Registration Statement, the General Disclosure Package and the Prospectus or a document incorporated by reference therein
and that is not so described. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Neither the Company nor any Subsidiary owns any &#147;margin
securities&#148; as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the &#147;<B>Federal Reserve Board</B>&#148;), and none of the proceeds of the Offering will be used, directly or indirectly, for the
purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Shares to be
considered a &#147;purpose credit&#148; within the meanings of Regulation T, U or X of the Federal Reserve Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(jj) Neither the Company nor any Subsidiary is a party to any contract, agreement or understanding with any person that would give rise to a valid claim against the Company or any Subsidiary or the
Underwriters for a brokerage commission, finder&#146;s fee or like payment in connection with the Offering or any transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(kk) No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of
the Exchange Act) contained in the Registration Statement, the General Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ll) The Company is subject to and in compliance in all material respects with the reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. The Common Stock is registered pursuant to Section&nbsp;12(b) of the Exchange Act and is listed on the Nasdaq CM, and the Company has taken no action designed to, or reasonably likely to
have the effect of, terminating the registration of the Common Stock under the </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Exchange Act or delisting the Common Stock from the Nasdaq CM, nor has the Company received any notification that the Commission or FINRA is contemplating terminating such registration or
listing. No consent, approval, authorization or order of, or filing, notification or registration with, the Nasdaq CM is required for the listing and trading of the Shares on the Nasdaq CM, except for (i)&nbsp;a Notification Form: Listing of
Additional Shares and (ii)&nbsp;a Notification Form: Change in the Number of Shares Outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(mm) The
Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) which are applicable to it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(nn) The Company is in material compliance with all applicable corporate governance requirements set forth in the Nasdaq Capital Marketplace Rules. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(oo) Neither the Company nor any Subsidiary nor, to the Company&#146;s knowledge, any employee or agent of the Company or
any Subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state, local or foreign office in violation of any law (including the Foreign Corrupt Practices Act of 1977, as amended) or of the
character required to be disclosed in the Registration Statement, the General Disclosure Package or the Prospectus or a document incorporated by reference therein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(pp) There are no transactions, arrangements or other relationships between and/or among the Company or any Subsidiary,
any of their respective affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that would reasonably be
expected to materially affect the Company&#146;s or any Subsidiary&#146;s liquidity or the availability of or requirements for its capital resources, which transaction, arrangement or other relationship is required to be described in the
Registration Statement, the General Disclosure Package and the Prospectus or any document incorporated by reference therein that has not been described as required. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(qq) There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of
business) or guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any of the officers or directors of the Company or any Subsidiary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(rr) The statistical and market related data included in the Registration Statement, the General Disclosure Package and
the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which they are derived. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ss) The operations of the Company and each Subsidiary are and have been conducted at all times in compliance with
applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
&#147;<B>Money Laundering Laws</B>&#148;), and no action, suit or </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending, or to
the Company&#146;s knowledge, threatened. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(tt) Neither the Company nor any Subsidiary nor, to the
Company&#146;s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(&#147;<B>OFAC</B>&#148;); and the Company will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity, for the
purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(uu) Except as disclosed by the Company to the Underwriters, neither the Company nor any Subsidiary nor, to the knowledge
of the Company, any of their respective affiliates (within the meaning of FINRA&#146;s NASD Conduct Rule 2720(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning
of Article I, Section&nbsp;1(ee) of the By-laws of FINRA) of, any member firm of FINRA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vv) The Company is,
and will be immediately following this Offering, in compliance with the rules for the use of a registration statement on Form S-3 as set forth in Instruction I.B.1, and is not, as of the date hereof, subject to the limitations under I.B.6 of Form
S-3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ww) No approval of the stockholders of the Company under the rules and regulations of Nasdaq (including
Rule 5635 of the Nasdaq Capital Marketplace Rules) is required for the Company to issue and deliver to the Underwriters the Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any certificate signed by or on behalf of the Company and delivered to the Underwriters or to counsel for the Underwriters shall be deemed to be a representation and warranty by the Company to the
Underwriters as to the matters covered thereby. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <I>F<SMALL>URTHER</SMALL> A<SMALL>GREEMENTS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></I><SMALL></SMALL>. The Company agrees with the Underwriters: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) To prepare the Rule 462(b) Registration Statement, if necessary, in a form approved by the Representative and file such Rule 462(b) Registration Statement with the Commission on the date hereof; to
prepare the Prospectus in a form approved by the Representative containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rules 430A, 430B or 430C of the Rules and Regulations and to file
such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than the second (2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;business day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by Rule 430A of the Rules and Regulations; to promptly notify the
Underwriters of the Company&#146;s intention to file or prepare any supplement or amendment to any Registration Statement or to the Prospectus in connection with the Offering and to make no </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
amendment or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus to which the Underwriters shall reasonably object by notice to the Company after a
reasonable period to review; to advise the Underwriters, promptly after it receives notice thereof, of the time when any amendment to any Registration Statement has been filed or becomes effective or any supplement to the General Disclosure Package
or the Prospectus or any amended Prospectus has been filed and to furnish the Underwriters with copies thereof; to file within the time periods prescribed by the Exchange Act, including any extension thereof, all material required to be filed by the
Company with the Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case may be; to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the
Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and
Regulations) is required in connection with the Offering; to advise the Underwriters, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary
Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any
request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure Package or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing
or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its best efforts to obtain the withdrawal of such order. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Company represents and agrees that it has not made and, unless it obtains the prior consent of the
Representative, it will not make any offer relating to the Units that would constitute a &#147;free writing prospectus&#148; as defined in Rule 405 of the Rules and Regulations (each, a &#147;<B>Permitted Free Writing Prospectus</B>&#148;);
<I>provided</I> that the prior written consent of the Representative shall be deemed to have been given in respect of the General Use Free Writing Prospectus, if any, included in <U>Schedule A</U> hereto. The Company represents that it has treated
and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including the
requirements relating to timely filing with the Commission, legending and record keeping and will not take any action that would result in any Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules
and Regulations a free writing prospectus prepared by or on behalf of the Underwriters that the Underwriters otherwise would not have been required to file thereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If at any time when a Prospectus relating to the Shares is required to be delivered under the Securities Act, any
event occurs or condition exists as a result of which the Prospectus, as then amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light
of the circumstances under which they were made, not </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
misleading, or the Registration Statement, as then amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein not misleading, or if for any other reason it is necessary at any time to amend or supplement any Registration Statement or the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus to comply
with the Securities Act or the Exchange Act, the Company will promptly notify the Underwriters, and upon the Representative&#146;s request, the Company will promptly prepare and file with the Commission, at the Company&#146;s expense, an amendment
to the Registration Statement or an amendment or supplement to the Prospectus or make an appropriate filing under Section&nbsp;13 or 14 of the Exchange Act that corrects such statement or omission or effects such compliance and will deliver to the
Underwriters, without charge, such number of copies thereof as the Underwriters may reasonably request. The Company consents to the use of the Prospectus or any amendment or supplement thereto by the Underwriters. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If the General Disclosure Package is being used to solicit offers to buy the Shares at a time when the Prospectus is
not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company or in the reasonable opinion of the Representative, it becomes necessary to amend or supplement the General Disclosure Package
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or to make the statements therein not conflict with the information contained or incorporated by reference in the Registration
Statement then on file and not superseded or modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company promptly will either (i)&nbsp;prepare, file with the Commission (if
required) and furnish to the Underwriters and any dealers an appropriate amendment or supplement to the General Disclosure Package or (ii)&nbsp;prepare and file with the Commission an appropriate filing under the Exchange Act which shall be
incorporated by reference in the General Disclosure Package so that the General Disclosure Package as so amended or supplemented will not, in the light of the circumstances under which they were made, be misleading or conflict with the Registration
Statement then on file, or so that the General Disclosure Package will comply with law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If at any time
following issuance of an Issuer Free Writing Prospectus in connection with the Offering there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information
contained in the Registration Statement, the Pricing Prospectus or the Prospectus, including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof and not superseded or modified or included or would
include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading, the Company has promptly notified or will promptly notify the Underwriters (and the Underwriters agree to cease such use promptly upon such notification) so that any use of the Issuer Free Writing Prospectus may cease until it is amended
or supplemented and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
omission. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to
the Company by the Underwriters specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) To the extent not available on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval
(&#147;<B>EDGAR</B>&#148;) system or any successor system, to furnish promptly to the Underwriters and to counsel for the Underwriters, a signed copy of the Registration Statement as originally filed with the Commission, and of each amendment
thereto filed with the Commission, including all consents and exhibits filed therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) To the extent not
available on the Commission&#146;s EDGAR system or any successor system, to deliver promptly to the Underwriters such number of the following documents as the Underwriters shall reasonably request: (i)&nbsp;conformed copies of the Registration
Statement as originally filed with the Commission (in each case excluding exhibits), (ii)&nbsp;any Preliminary Prospectus, (iii)&nbsp;any Issuer Free Writing Prospectus, (iv)&nbsp;the Prospectus (the delivery of the documents referred to in clauses
(i), (ii), (iii)&nbsp;and (iv)&nbsp;of this <U>paragraph (g)</U>&nbsp;to be made not later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement), (v)&nbsp;conformed copies of any amendment to the
Registration Statement (excluding exhibits), (vi)&nbsp;any amendment or supplement to the General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v)&nbsp;and (vi)&nbsp;of this <U>paragraph (g)</U>&nbsp;to
be made not later than 10:00 A.M., New York City time, on the business day following the date of such amendment or supplement) and (vii)&nbsp;any document incorporated by reference in the General Disclosure Package or the Prospectus (excluding
exhibits thereto) (the delivery of the documents referred to in clause (vi)&nbsp;of this <U>paragraph (g)</U>&nbsp;to be made not later than 10:00 A.M., New York City time, on the business day following the date of such document). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) To make generally available to its stockholders as soon as practicable, but in any event not later than eighteen
(18)&nbsp;months after the effective date of each Registration Statement, an earning statement (as defined in Rule 158(c) of the Rules and Regulations) of the Company and its Subsidiaries (which need not be audited) complying with Section&nbsp;11(a)
of the Securities Act and the Rules and Regulations (including, at the option of the Company, Rule 158). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)
To take promptly from time to time such actions as the Underwriters may reasonably request to qualify any of the Shares for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Underwriters may
reasonably designate and to continue such qualifications in effect, and to comply with such laws, for so long as required for the distribution of any of the Shares; <I>provided </I>that the Company shall not be obligated to qualify as a foreign
corporation in any jurisdiction in which it is not so qualified or to file a general consent to service of process in any jurisdiction. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) Upon request, during the period of three (3)&nbsp;years from the date
hereof, to the extent not available on the Commission&#146;s EDGAR system, the Company will deliver to the Underwriters, (i)&nbsp;upon request, copies of all reports or other communications furnished to stockholders and (ii)&nbsp;upon request,
copies of any reports and financial statements furnished or filed with the Commission pursuant to the Exchange Act or any national securities exchange or automatic quotation system on which the Common Stock is listed or quoted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) That the Company will not, for a period of thirty (30)&nbsp;days from the date of this Agreement, (the
&#147;<B>Lock-Up Period</B>&#148;) without the prior written consent of the Representative, directly or indirectly offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock at an effective price per share less than the Public Offering Price, other than (i)&nbsp;the Shares, (ii)&nbsp;the issuance of Common Stock, restricted Common Stock or options to
acquire Common Stock in each case pursuant to the Company&#146;s employee benefit plans, qualified stock option plans, employee stock purchase plan or other employee compensation plans as such plans are in existence on the date hereof and described
in the Registration Statement, the General Disclosure Package and the Prospectus, (iii)&nbsp;the issuance of Common Stock pursuant to the valid exercises of options, warrants or rights outstanding on the date hereof and (iv)&nbsp;the issuance of
securities of the Company in connection with collaboration, licensing or business development transactions, mergers or acquisitions, any reorganization, recapitalization or similar transaction. The Company will cause each executive officer and
director listed in <U>Schedule B</U> to furnish to the Underwriters, prior to the Closing Date, a letter, substantially in the form of <U>Exhibit A</U> hereto. The Company also agrees that during the Lock-Up Period, the Company will not file any
registration statement, preliminary prospectus or prospectus, or any amendment or supplement thereto, under the Securities Act for any such transaction or which registers, or offers for sale, Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock, except for the RXi Registration Statement and except for a registration statement on Form S-8 relating to employee benefit plans. The Company hereby agrees that (i)&nbsp;if it issues an earnings release
or material news, or if a material event relating to the Company occurs, during the last seventeen (17)&nbsp;days of the Lock-Up Period, or (ii)&nbsp;if prior to the expiration of the Lock-Up Period, the Company announces that it will release
earnings results during the sixteen (16)-day period beginning on the last day of the Lock-Up Period, unless waived by the Representative, the restrictions imposed by this <U>paragraph (k)</U>&nbsp;or the letter shall continue to apply until the
expiration of the eighteen (18)-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(l) To supply the Underwriters with copies of all correspondence to and from, and all documents issued to and by, the Commission in connection with the registration of the Shares under the Securities Act
or the Registration Statement, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) Prior to the Closing Date or any Option Closing Date, to furnish to the
Underwriters, promptly after they have been prepared (to the extent they have been prepared), copies of any unaudited interim consolidated financial statements of the Company for any periods subsequent to the periods covered by the financial
statements appearing in or incorporated by reference into the Registration Statement and the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n)
Prior to the Closing Date or any Option Closing Date, not to issue any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business
affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past practices of the Company), without the prior written consent of the Representative, which consent shall
not be unreasonably withheld, conditioned or delayed, unless in the judgment of the Company and its counsel, and after notification to the Underwriters, such press release or communication is required by law or applicable stock exchange rules.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) Until the Representative shall have notified the Company of the completion of the Offering, the Company
will not, and will cause its affiliated purchasers (as defined in Regulation M under the Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated purchasers has a
beneficial interest, any Shares, or attempt to induce any person to purchase any Shares; and not to, and to cause its affiliated purchasers not to, make bids or purchases for the purpose of creating actual, or apparent, active trading in or of
raising the price of the Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p) Not to take any action prior to the Closing Date or any Option closing
Date that would require the Prospectus to be amended or supplemented pursuant to <U>Section 4</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) To at
all times comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(r) To apply the net proceeds from the Offering as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(s) To use its best efforts to file and obtain conditional and final clearance from FINRA, or to assist the Underwriters
with any filings with FINRA and obtaining final clearance from FINRA, as to the Registration Statement and the Prospectus and as to amount of compensation allowable or payable to the Underwriters. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(t) To use its commercially reasonable best efforts to list, effect and maintain, subject to notice of issuance, the
Common Stock on the Nasdaq CM. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(u) To use its commercially reasonable best efforts to do and perform all
things required to be done or performed under this Agreement by the Company prior to </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Closing Date and any Option Closing Date and to satisfy all conditions precedent to the delivery of the Shares, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <I>P<SMALL>AYMENT</SMALL> <SMALL>OF</SMALL> E<SMALL>XPENSES</SMALL></I><SMALL></SMALL>. The Company, whether or not the transactions
contemplated hereby are consummated or this Agreement is terminated, agrees to pay, or reimburse if paid by the Underwriters: (a)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares to the
Underwriters and any taxes payable in that connection; (b)&nbsp;the costs incident to the registration of the Shares under the Securities Act; (c)&nbsp;the costs incident to the preparation, printing and distribution of the Registration Statement,
the Base Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto or any document incorporated by reference therein and the costs of
printing, reproducing and distributing any transaction document by mail, telex or other means of communications; (d)&nbsp;the reasonable and documented fees and expenses (including related fees and expenses of counsel for the Underwriters) incurred
in connection with securing any required review by FINRA of the terms of the Offering and any filings made with FINRA; (e)&nbsp;any applicable listing, quotation or other fees; (f)&nbsp;the reasonable and documented fees and expenses (including
related fees and expenses of counsel to the Underwriters) of qualifying the Shares under the securities laws of the several jurisdictions as provided in <U>Section&nbsp;4(i)</U> and of preparing, printing and distributing wrappers, Blue Sky
Memoranda and Legal Investment Surveys (if any); (g)&nbsp;the cost of preparing and printing stock certificates, if necessary; (h)&nbsp;all fees and expenses of the registrar and transfer agent of the shares of Common Stock, (i)&nbsp;all reasonable
and documented fees, disbursements and expenses of counsel to the Underwriters and (j)&nbsp;all other costs and expenses incident to the Offering by, or the performance of the obligations of, the Company under this Agreement (including, without
limitation, the reasonable and documented fees and expenses of the Company&#146;s counsel and the Company&#146;s independent accountants and the travel and other expenses actually incurred by Company and the Underwriters&#146; personnel in
connection with any &#147;road show&#148; including, without limitation, any expenses advanced by the Underwriters on the Company&#146;s behalf (which will be promptly reimbursed)). Notwithstanding the provisions of this <U>Section&nbsp;5</U>, in no
event (i)&nbsp;shall the Company be obligated to reimburse the Underwriters and their counsel for aggregate expenses pursuant to this <U>Section&nbsp;5</U> (i)&nbsp;in excess of $35,000 and (ii)&nbsp;shall the maximum compensation payable to FINRA
members and independent broker-dealers exceed 8.0% of the gross proceeds of the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <I>C<SMALL>ONDITIONS</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> O<SMALL>BLIGATIONS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> U<SMALL>NDERWRITERS</SMALL>, <SMALL>AND</SMALL> <SMALL>THE</SMALL> S<SMALL>ALE</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
S<SMALL>HARES</SMALL></I><SMALL></SMALL>. The obligations of the Underwriters hereunder, and the closing of the Offering, are subject to the accuracy, when made and as of the Applicable Time, on the Closing Date and on any Option Closing Date, of
the representations and warranties of the Company contained herein, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to
each of the following additional terms and conditions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Registration Statement is effective under the
Securities Act, and no stop order suspending the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Base Prospectus, any Preliminary Prospectus, the Prospectus or any Permitted Free Writing
Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section&nbsp;8A under the Securities </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Act shall have been initiated or threatened by the Commission, and all requests for additional information on the part of the Commission (to be included or incorporated by reference in the
Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Underwriters; the Rule 462(b) Registration Statement, if any, any Issuer Free Writing Prospectus, and the Prospectus shall
have been filed with the Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance with <U>Section&nbsp;4 (a)</U>, and the Rule 462(b) Registration Statement, if
any, shall have become effective immediately upon its filing with the Commission; and, if applicable, FINRA shall have raised no objection to the fairness and reasonableness of the terms of this Agreement or the transactions contemplated hereby.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Underwriters shall not have discovered and disclosed to the Company on or prior to the Closing Date
or any Option Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact that, in the opinion of counsel for the Underwriters, is material or omits to state any fact which, in the
opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus or any amendment or
supplement thereto contains an untrue statement of fact that, in the opinion of such counsel, is material or omits to state any fact that, in the opinion of such counsel, is material and is necessary in order to make the statements, in the light of
the circumstances in which they were made, not misleading. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) All corporate proceedings and other legal
matters incident to the authorization, form and validity of each of this Agreement, the Shares, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus, if any, and the Prospectus and all other legal matters
relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters, and the Company shall have furnished to such counsel all documents and information that
they may reasonably request to enable them to pass upon such matters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) TroyGould PC shall have furnished
to the Underwriters, such counsel&#146;s written opinion and negative assurances statement, as counsel to the Company, addressed to the Underwriters and dated the Closing Date or the Option Closing Date, as applicable, in the form and substance
reasonably satisfactory to the Underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Nelson Mullins Riley&nbsp;&amp; Scarborough LLP shall have
furnished to the Underwriters, such counsel&#146;s written opinion, as intellectual property counsel to the Company, addressed to the Underwriters and dated the Closing Date or the Option Closing Date, as applicable, in the form and substance
reasonably satisfactory to the Underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) At the time of the execution of this Agreement, the
Underwriters shall have received from BDO USA, LLP, a letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Underwriters (i)&nbsp;confirming
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that they are an independent registered accounting firm with respect to the Company within the meaning of the Securities Act and the Rules and Regulations and the PCAOB and (ii)&nbsp;stating the
conclusions and findings of such firm, of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters, with respect to the financial statements and certain financial information relating to the Company contained or
incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) On the effective date of any post-effective amendment to any Registration Statement, on the Closing Date and on any
Option Closing Date, the Underwriters shall have received a letter (the &#147;<B>BDO Bring-Down Letter</B>&#148;) from BDO USA, LLP addressed to the Underwriters and dated the Closing Date or the Option Closing Date, as applicable, confirming, as of
the date of the BDO Bring-Down Letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package and the Prospectus, as the case
may be, as of a date not more than three (3)&nbsp;business days prior to the date of the Bring-Down Letter), the conclusions and findings of such firm, of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters,
with respect to the financial information and other matters relating to the Company covered by its letter delivered to the Underwriters concurrently with the execution of this Agreement pursuant to paragraph (g)&nbsp;of this <U>Section 6</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) The Company shall have furnished to the Underwriters a certificate, dated the Closing Date, or the Option
Closing Date, as applicable, of its President or Chief Executive Officer and its Treasurer stating in their capacities as officers of the Company that (i)&nbsp;such officers have carefully examined the Registration Statement, the General Disclosure
Package, any Permitted Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, at the Applicable Time and as of the date of this Agreement and as of the Closing Date or the Option
Closing Date, as applicable, did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the General Disclosure
Package, as of the Applicable Time and as of the Closing Date or the Option Closing Date, as applicable, any Permitted Free Writing Prospectus as of its date and as of the Closing Date or the Option Closing Date, as applicable, and the Prospectus
and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date or the Option Closing Date, as applicable, did not include any untrue statement of a material fact and did not omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii)&nbsp;since the effective date of the Registration Statement, no event has occurred that should have been set forth in
a supplement or amendment to the Registration Statement, the General Disclosure Package or the Prospectus that has not been so set forth therein, (iii)&nbsp;to the best of their knowledge after reasonable investigation, as of the Closing Date or the
Option Closing Date, as applicable, the representations and warranties of the Company in this Agreement are true and correct in all material respects (except that to the extent that any representations and warranties are qualified as to materiality,
then such representations and warranties shall be true and correct in all respects) and the Company </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Option Closing
Date, as applicable, and (iv)&nbsp;there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference in the General Disclosure Package, any material adverse change in the financial
position or results of operations of the Company or any Subsidiary, or any change or development that, singly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition
(financial or otherwise), results of operations, business, assets or prospects of the Company or any Subsidiary, except as set forth in the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Since the date of the latest audited financial statements included in the Registration Statement, the General Disclosure Package or the Prospectus or incorporated by reference in the Registration
Statement, the General Disclosure Package or the Prospectus as of the date hereof, (i)&nbsp;neither the Company nor any Subsidiary shall have sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether
or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, and (ii)&nbsp;there shall not have
been any change in the capital stock (other than Excluded Issuances) or long-term debt of the Company or any Subsidiary, or any change, or any development involving a prospective change, in or affecting the business, general affairs, management,
financial position, stockholders&#146; equity or results of operations of the Company or any Subsidiary, otherwise than as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, the effect of which, in any such
case described in clause (i)&nbsp;or (ii)&nbsp;of this <U>paragraph (i)</U>, is, in the judgment of the Underwriters, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Shares on the terms
and in the manner contemplated in the Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(j) No action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would prevent the issuance or sale of
the Shares or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company or any Subsidiary; and no injunction, restraining order or order of any other nature by any federal or state court
of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Shares or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company or any Subsidiary.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the
following: (i)&nbsp;trading in securities generally on the New York Stock Exchange, Nasdaq GM, Nasdaq CM or the NYSE Amex LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter
market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established on any such exchange or such market by the Commission, by such exchange or market or by any
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other regulatory body or governmental authority having jurisdiction, (ii)&nbsp;a banking moratorium shall have been declared by Federal or state authorities or a material disruption has occurred
in commercial banking or securities settlement or clearance services in the United States, (iii)&nbsp;the United States shall have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or
escalation in hostilities involving the United States, or there shall have been a declaration of a national emergency or war by the United States or (iv)&nbsp;there shall have occurred such a material adverse change in general economic, political or
financial conditions (or the effect of international conditions on the financial markets in the United States shall be such) as to make it, in the judgment of the Underwriters, impracticable or inadvisable to proceed with the sale or delivery of the
Shares on the terms and in the manner contemplated in the Registration Statement, the General Disclosure Package and the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(l) The Company shall have filed a Notification: Listing of Additional Shares covering the Shares with the Nasdaq CM and the Company shall not have received an objection thereto from the Nasdaq CM.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) FINRA shall not have objected to the terms of the Offering or the compensation allowable or payable to
the Underwriters as described in the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) The Underwriters shall have received the written
agreements, substantially in the form of <U>Exhibit A</U> hereto, of the executive officers and directors of the Company listed in <U>Schedule B</U> to this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) The Company shall have prepared and filed with the Commission a Current Report on Form 8-K with respect to the
Offering, which shall include as an exhibit thereto this Agreement and a press release related to and describing the material terms of this Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(p) On or prior to the Closing Date or the Option Closing Date, as applicable, the Company shall have furnished to the Underwriters such further information, good standing documents, due authorizations
and consents, opinions, certificates, comfort or other letters or documents as the Underwriters shall have reasonably requested related to the issuance of the Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All opinions, letters, evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance
reasonably satisfactory to counsel for the Underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <I>I<SMALL>NDEMNIFICATION</SMALL> <SMALL>AND</SMALL>
C<SMALL>ONTRIBUTION</SMALL></I><SMALL></SMALL>. (a) The Company shall indemnify and hold harmless each of the Underwriters, each of its affiliates and each of its and their respective directors, officers, members, employees, representatives and
agents and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively the &#147;<B>Underwriter Indemnified Parties,</B>&#148; and each a
&#147;<B>Underwriter Indemnified Party</B>&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage,
expense, liability, action, investigation or proceeding arises out of or is based upon (A)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any
&#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein,
(B)&nbsp;the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any
Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, a material fact required to be stated therein or necessary to make the statements therein not misleading, or
(C)&nbsp;any breach of the representations and warranties of the Company contained herein or the failure of the Company to perform its obligations hereunder or pursuant to any law, and shall reimburse the Underwriter Indemnified Party promptly upon
demand for any legal fees or other expenses reasonably incurred by the Underwriter Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as a third party witness in respect of, or otherwise
incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred; <I>provided, however</I>, that the Company shall not be liable in any such case to the extent
that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus, any Registration Statement or the Prospectus,
or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by such Underwriter specifically for use therein, which information the
parties hereto agree is limited to the Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>). This indemnity agreement in this <U>Section&nbsp;7(a) </U>is not exclusive and is and will be in addition to any liability, which the
Company might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Underwriter Indemnified Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each Underwriter, severally but not jointly, shall indemnify and hold harmless the Company and its directors, its
officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively the &#147;<B>Company Indemnified
Parties</B>&#148; and each a &#147;<B>Company Indemnified Party</B>&#148;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such Company
Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration
Statement or the Prospectus, or in any amendment or supplement thereto, or (ii)&nbsp;the omission or alleged omission to state in any Preliminary </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the extent that the untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by such Underwriter specifically for use therein, which information the parties hereto agree is limited to the
Underwriters&#146; Information (as defined in <U>Section&nbsp;18</U>), and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or
defending against or appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. This indemnity agreement in this <U>Section&nbsp;7(b)</U>
is not exclusive and will be in addition to any liability which any Underwriter might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Company Indemnified Party. Notwithstanding
the provisions of this <U>Section&nbsp;7(b)</U>, in no event shall any indemnity by any Underwriter under this <U>Section&nbsp;7(b)</U> exceed the total discount and commission received by such Underwriter in connection with this Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Promptly after receipt by an indemnified party under this <U>Section&nbsp;7</U> of notice of the
commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 7</U>, notify such indemnifying party in writing of the commencement of that action;
<I>provided, however</I>, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this <U>Section&nbsp;7</U> except to the extent it has been materially prejudiced by such failure; and,
<I>provided, further</I>, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this <U>Section&nbsp;7</U>. If any such action shall be brought against
an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the
defense of such action with counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party). After notice from the indemnifying party
to the indemnified party of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section&nbsp;7</U> for any legal or other expenses subsequently
incurred by the indemnified party in connection with the defense of such action other than reasonable costs of investigation; <I>provided, however</I>, that any indemnified party shall have the right to employ separate counsel in any such action and
to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i)&nbsp;the employment thereof has been specifically
authorized in writing by the Company in the case of a claim for indemnification under <U>Section&nbsp;7(a)</U> or <U>Section&nbsp;2.4</U> or the Underwriters in the case of a claim for indemnification under <U>Section&nbsp;7(b)</U>, (ii)&nbsp;such
indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are different from or additional to those available to the indemnifying party, or (iii)&nbsp;the indemnifying party has failed to assume the defense of such action and employ counsel reasonably
satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such
indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure
to diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such
indemnified party in connection with the defense of such action; <I>provided, however</I>, that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same
jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel),
which firm shall be designated in writing by the Underwriters if the indemnified parties under this <U>Section&nbsp;7</U> consist of any Underwriter Indemnified Party or by the Company if the indemnified parties under this <U>Section&nbsp;7</U>
consist of any Company Indemnified Parties. Subject to this <U>Section&nbsp;7(c)</U>, the amount payable by an indemnifying party under <U>Section&nbsp;7</U> shall include, but not be limited to, (x)&nbsp;reasonable legal fees and expenses of
counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation,
proceeding or claim, and (y)&nbsp;all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of judgment with
respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this <U>Section&nbsp;7</U> (whether or not the indemnified parties are actual or potential parties
thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability arising out of such action or
claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable for
settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been
unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such settlement
or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement
of the nature contemplated herein effected without its written consent if (i)&nbsp;such settlement is entered into more than forty-five (45)&nbsp;days after receipt by such indemnifying party of the request for reimbursement, (ii)&nbsp;such
indemnifying party shall have received notice of the terms of </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such settlement at least thirty (30)&nbsp;days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance
with such request prior to the date of such settlement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If the indemnification provided for in this
<U>Section&nbsp;7</U> is unavailable or insufficient to hold harmless an indemnified party under <U>Section&nbsp;7(a)</U> or <U>Section&nbsp;7(b)</U>, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to
the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i)&nbsp;in such proportion as shall
be appropriate to reflect the relative benefits received by the Company on the one hand and such Underwriter on the other hand from the Offering, or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;of this <U>Section&nbsp;7(d)</U> is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;of this <U>Section&nbsp;7(d)</U> but also the relative fault of the Company on the one hand and such
Underwriter on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one hand and any Underwriter on the other with respect to such offering shall be deemed to be in the same proportion as the total net proceeds from the Offering
under this Agreement (before deducting expenses) received by the Company bear to the total discount and commission received by such Underwriter in connection with the Offering, in each case as set forth in the table on the cover page of the
Prospectus and in the &#147;Underwriting&#148; section thereof. The relative fault of the Company on the one hand and any Underwriter on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or such Underwriter on the other, the intent of the parties and their relative knowledge, access
to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the parties hereto agree that the written information furnished to the Company by the Underwriters for use in any Preliminary
Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters&#146; Information as defined in <U>Section&nbsp;18</U>. The Company and each Underwriter agree that it would not
be just and equitable if contributions pursuant to this <U>Section&nbsp;7(d)</U> were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The
amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this <U>Section&nbsp;7(d)</U> shall be deemed to include, for purposes of this
<U>Section&nbsp;7(d)</U>, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred
in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this <U>Section&nbsp;7(d)</U>, no Underwriter shall be required to contribute any amount in excess of the
total discount and commission received by such Underwriter in connection with this Offering less the amount of any damages which such Underwriter </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No
person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <I>D<SMALL>EFAULT</SMALL> <SMALL>OF</SMALL> O<SMALL>NE</SMALL> <SMALL>OR</SMALL> M<SMALL>ORE</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> S<SMALL>EVERAL</SMALL> U<SMALL>NDERWRITERS</SMALL></I><SMALL></SMALL>. If, on the Closing Date or any Option Closing Date, as the case may be, any one or more of the several Underwriters shall fail or refuse to purchase Shares
that it or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of Shares to be
purchased on such date, the Representative may make arrangements satisfactory to the Company for the purchase of such Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other
Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule I</U> bears to the aggregate number of Firm Shares set forth opposite the names of
all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with the consent of the non-defaulting Underwriters, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but
failed or refused to purchase on such date. If, on the Closing Date or the applicable Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares with
respect to which such default occurs exceeds 10% of the aggregate number of Shares to be purchased on such date, and arrangements satisfactory to the Representative and the Company for the purchase of such Shares are not made within 24 hours after
such default, this Agreement or the obligation to purchase Shares on an Option Closing Date, as applicable, shall terminate without liability of any party to any other party, except that the provisions of <U>Sections 5</U>, <U>7</U>, <U>9</U>,
<U>12, 13</U> and <U>14</U> shall at all times be effective and shall survive such termination. In any case where such a default does not result in a termination of this Agreement or the obligation of the Underwriters to purchase Shares on the
Closing Date or an Option Closing Date, as applicable, either the Representative or the Company shall have the right to postpone the Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days
in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9. <I>T<SMALL>ERMINATION</SMALL></I><SMALL></SMALL>. The obligations of the Underwriters hereunder may be terminated by the Underwriters, in their absolute discretion by notice given to the Company prior
to delivery of and payment for the Shares if, prior to that time, any of the events described in <U>Section&nbsp;6(i)</U>, <U>Section&nbsp;6(j)</U> or <U>Section&nbsp;6(k)</U> have occurred or if the Underwriters shall decline to purchase the Shares
for any reason permitted under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <I>R<SMALL>EIMBURSEMENT</SMALL> <SMALL>OF</SMALL>
U<SMALL>NDERWRITERS</SMALL>&#146; E<SMALL>XPENSES</SMALL></I><SMALL></SMALL>. Notwithstanding anything to the contrary in this Agreement, if (a)&nbsp;this Agreement shall have been terminated pursuant to <U>Section&nbsp;8</U> or
<U>Section&nbsp;9</U>, (b)&nbsp;the Company shall fail to tender any of the Shares for delivery to the Underwriters for any reason not permitted under this Agreement, (c)&nbsp;the Underwriters shall decline to purchase the Shares for any reason
permitted under this Agreement or (d)&nbsp;the Offering </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
is not consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to
perform any agreement herein or to satisfy any condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with <U>Section&nbsp;5</U>, the Company shall reimburse the Underwriters for the reasonable
and documented fees and expenses of the Underwriters&#146; counsel and for such other accountable out-of-pocket expenses as shall have been reasonably incurred by the Underwriters in connection with this Agreement and the proposed purchase of the
Shares, and upon demand the Company shall pay the full amount thereof to the Underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.
<I>E<SMALL>FFECTIVENESS</SMALL></I><SMALL></SMALL>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12. <I>A<SMALL>BSENCE</SMALL> <SMALL>OF</SMALL> F<SMALL>IDUCIARY</SMALL> R<SMALL>ELATIONSHIP</SMALL></I><SMALL></SMALL>. The Company acknowledges and agrees that: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) each Underwriter&#146;s responsibility to the Company is solely contractual in nature, such Underwriter has been
retained solely to act as an underwriter in connection with the Offering and no fiduciary, advisory or agency relationship between the Company and such Underwriter has been created in respect of any of the transactions contemplated by this
Agreement, irrespective of whether such Underwriter has advised or is advising the Company on other matters; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the price of the Shares set forth in this Agreement was established by the Company following discussions and
arms-length negotiations with the Underwriters, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) it has been advised that each Underwriter and its affiliates are engaged in a broad range of transactions which may
involve interests that differ from those of the Company and that such Underwriter has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) it waives, to the fullest extent permitted by law, any claims it may have against each Underwriter for breach of
fiduciary duty or alleged breach of fiduciary duty and agrees that such Underwriter shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on
behalf of or in right of the Company, including stockholders, employees or creditors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.
<I>S<SMALL>UCCESSORS</SMALL>; P<SMALL>ERSONS</SMALL> E<SMALL>NTITLED</SMALL> <SMALL>TO</SMALL> B<SMALL>ENEFIT</SMALL> <SMALL>OF</SMALL> A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>. This Agreement shall inure to the benefit of and be binding upon the
Underwriters, the Company, and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, other than the persons mentioned in the preceding sentences, any legal or
equitable right, remedy or claim under or in respect of this Agreement, or any </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provisions herein contained, this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no
other person; except that the representations, warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter Indemnified Parties and the indemnity of the Underwriters
shall be for the benefit of the Company Indemnified Parties. It is understood that the Underwriters&#146; responsibility to the Company is solely contractual in nature and that no Underwriter owes the Company, or any other party, any fiduciary duty
as a result of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <I>S<SMALL>URVIVAL</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEMNITIES</SMALL>,
R<SMALL>EPRESENTATIONS</SMALL>, W<SMALL>ARRANTIES</SMALL>, <SMALL>ETC</SMALL></I><SMALL></SMALL>. The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and the Underwriters, as set forth
in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of the Underwriters, the Company or any person controlling any of them and shall
survive delivery of and payment for the Shares. Notwithstanding any termination of this Agreement, including without limitation any termination pursuant to <U>Section&nbsp;8</U> or <U>Section&nbsp;9</U>, the indemnity and contribution and
reimbursement agreements contained in <U>Sections 7</U> and <U>10</U> and the covenants, representations, warranties set forth in this Agreement shall not terminate and shall remain in full force and effect at all times. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. <I>N<SMALL>OTICES</SMALL></I><SMALL></SMALL>. All statements, requests, notices and agreements hereunder shall be in writing, and:
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) if to the Underwriters, shall be delivered or sent by overnight courier, facsimile transmission or email
to Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, Attention: Head of Equity Capital Markets, Fax: (949)&nbsp;720-7227; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) if to the Company, shall be delivered or sent by overnight courier, email or facsimile transmission to: Galena Biopharma, Inc., 310 N. State Street, Suite 208, Lake Oswego, Oregon 97034, Fax:
(855)&nbsp;883-7422, Attention: Chief Executive Officer, with a copy to TroyGould PC, 1801 Century Park East, Suite 1600, Los Angeles, California, Attention: Dale E. Short, Esq., Fax: (310)&nbsp;789-1459; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any such statements, requests, notices or agreements shall take effect at the time of receipt thereof, except that any such statement, request, notice or
agreement delivered or sent by email shall take effect at the time of confirmation of receipt thereof by the recipient thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16. <I>D<SMALL>EFINITION</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> T<SMALL>ERMS</SMALL></I><SMALL></SMALL>. For purposes of this
Agreement, (a)&nbsp;&#147;<B>business day</B>&#148; means any day on which the New York Stock Exchange, Inc. is open for trading and (b)&nbsp;&#147;<B>knowledge</B>&#148; means the knowledge of the executive officers and directors of the Company
after reasonable inquiry. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17. <I>G<SMALL>OVERNING</SMALL> L<SMALL>AW</SMALL>, A<SMALL>GENT</SMALL> <SMALL>FOR</SMALL>
S<SMALL>ERVICE</SMALL> <SMALL>AND</SMALL> J<SMALL>URISDICTION</SMALL></I><SMALL></SMALL>. <B>This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation Section&nbsp;5-1401 of
the New York General Obligations Law. </B>No legal proceeding may be commenced, prosecuted or continued in any court other than the courts of the </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
State of New York located in the City and County of New York or in the United States District Court for the Southern District of New York, which courts shall have jurisdiction over the
adjudication of such matters, and the Company and each Underwriter hereby consent to the jurisdiction of such courts and personal service with respect thereto. The Company and each Underwriter hereby waive all right to trial by jury in any legal
proceeding (whether based upon contract, tort or otherwise) in any way arising out of or relating to this Agreement. The Company agrees that a final judgment in any such legal proceeding brought in any such court shall be conclusive and binding upon
the Company and the Underwriters and may be enforced in any other courts in the jurisdiction of which the Company is or may be subject, by suit upon such judgment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">18. <I>U<SMALL>NDERWRITERS</SMALL>&#146; I<SMALL>NFORMATION</SMALL></I><SMALL></SMALL>. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriters&#146;
Information consists solely of the following information in the Prospectus: (i)&nbsp;the fifth paragraph on the front cover page concerning the terms of the offering by the Underwriters; and (ii)&nbsp;the statements concerning the terms of the
offering contained in the fourth paragraph, concerning stabilization by the Underwriters in the ninth paragraph, and concerning electronic distributions in the eleventh paragraph, in each case under the heading &#147;Underwriting.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19. <I>P<SMALL>ARTIAL</SMALL> U<SMALL>NENFORCEABILITY</SMALL></I><SMALL></SMALL>. The invalidity or unenforceability of any section,
paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">20. <I>G<SMALL>ENERAL</SMALL></I><SMALL></SMALL>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral
agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and neuter genders and the singular and the plural include one another. The section headings in this Agreement are for
the convenience of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified, and the observance of any term of this Agreement may be waived, only by a writing signed by the
Company and the Underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21. <I>R<SMALL>ESEARCH</SMALL> A<SMALL>NALYST</SMALL>
I<SMALL>NDEPENDENCE</SMALL></I><SMALL></SMALL>. The Company acknowledges that each Underwriter&#146;s research analysts and research department are required to be independent from its investment banking division and are subject to certain
regulations and internal policies, and that each Underwriter&#146;s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the Offering that differ from
the views of their investment banking division. The Company acknowledges that each Underwriter is a full service securities firm and as such from time to time, subject to applicable securities laws, rules and regulations, may effect transactions for
its own account or the account of its customers and hold long or short positions in debt or equity securities of the Company; provided, however, that nothing in this <U>Section&nbsp;21</U> shall relieve any Underwriter of any responsibility or
liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules or regulations. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">22. <I>C<SMALL>OUNTERPARTS</SMALL></I><SMALL></SMALL>. This Agreement may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument and such signatures may be delivered by facsimile or by e-mail delivery of a &#147;.pdf&#148;
format data file. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the foregoing is in accordance with your understanding of the agreement between the
Company and the Underwriters, kindly indicate your acceptance in the space provided for that purpose below. </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very truly yours,</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and
Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confirmed as of the date first above-
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">mentioned by the Representative of the Underwriters. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ROTH CAPITAL PARTNERS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Aaron Gurewitz</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aaron Gurewitz</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Head of
Equity Capital Markets</FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<I>Signature Page to Underwriting
Agreement</I>] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE I </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Option&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roth Capital Partners, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,950,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">892,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cantor Fitzgerald&nbsp;&amp; Co.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodman&nbsp;&amp; Renshaw, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE A </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General Use Free Writing Prospectuses </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE B </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>List of officers and directors subject to <U>Section 4(k)</U> </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Directors </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn, Ph.D. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard Chin, M.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen S. Galliker
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanford J. Hillsberg </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven A.
Kriegsman </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rudolph Nisi, M.D. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Section&nbsp;16 Officers </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang
Lee </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pamela Pavco, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark W.
Schwartz </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT A </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form of Director and Officer Lock Up Agreement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;2, 2012 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roth Capital Partners, LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">888 San Clemente Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Newport Beach, CA 92660
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Galena Biopharma, Inc. &#151; Public Offering of Shares of Common Stock</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dear Sirs: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement is being delivered to you in connection with the
Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) by and between Galena Biopharma, Inc. (f/k/a RXi Pharmaceuticals Corporation), a Delaware corporation (the &#147;<B>Company</B>&#148;), and Roth Capital Partners, LLC, as the
representative (the &#147;<B>Representative</B>&#148;) of the several underwriters named therein (the &#147;<B>Underwriters</B>&#148;), relating to the proposed public offering of shares of common stock, par value $0.0001 per share (the
&#147;<B>Common Stock</B>&#148;), of the Company (the &#147;<B>Offering</B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to induce the Underwriters to
enter into the Underwriting Agreement, and in light of the benefits that the Offering will confer upon the undersigned in his or her capacity as a security holder and/or an officer, director or employee of the Company, and for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Underwriters that, for a period (the &#147;<B>Lock-Up Perio</B>d&#148;) of thirty (30)&nbsp;days following the date of the final prospectus
filed by the Company with the Securities and Exchange Commission in connection with the Offering, the undersigned will not, without the prior written consent of the Representative, directly or indirectly, (i)&nbsp;offer, sell, assign, transfer,
pledge, contract to sell, or otherwise dispose of, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock or announce the intention to otherwise dispose of, any Common Stock (including, without
limitation, shares of Common Stock or any such securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated under the Securities Act of 1933, as the same may be amended or
supplemented from time to time (such shares, the &#147;<B>Beneficially Owned Shares</B>&#148;)), (ii)&nbsp;enter into any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the
Beneficially Owned Shares or securities convertible into or exercisable or exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of
disposition, or (iii)&nbsp;engage in any short selling of the Common Stock or securities convertible into or exercisable or exchangeable for Common Stock. To the extent any Underwriter is at such time providing research coverage to the Company and
subject to the restrictions set forth in FINRA Rule 2711(f)(4), then if (a)&nbsp;the Company issues an earnings release or material news or a material event relating to the Company occurs during the last seventeen (17)&nbsp;days of the Lock-Up
Period, or (b)&nbsp;prior to the expiration of the Lock-Up Period, </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Company announces that it will release earnings results during the sixteen (16)-day period beginning on the last day of the Lock-Up Period, then in each case the Lock-Up Period shall be
extended and the restrictions imposed by this Agreement shall continue to apply until the expiration of the eighteen (18)-day period beginning on the date of the issuance of the earnings release or the occurrence of the material news or material
event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, the undersigned may (a)&nbsp;transfer any or all of the shares of Common Stock or other
Company securities if the transfer is (i)&nbsp;by gift, will or intestacy, (ii)&nbsp;to a trust the beneficiaries of which are the undersigned or a member or members of the immediate family of the undersigned, or (iii)&nbsp;transfers pursuant to a
sale or an offer to purchase 100% of the outstanding Common Stock, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties and (b)&nbsp;enter into a trading plan established in accordance with Rule 10b5-1
under the Securities Exchange Act of 1934, as amended, provided that no sale or other disposition under such plan may occur during the Lock-up Period; provided that in the case of any transfer or distribution pursuant to clause (a), each donee,
pledgee, distributee or transferee shall sign and deliver a lock-up agreement substantially in the form of this Agreement. For the purposes of this paragraph, &#147;immediate family&#148; shall mean spouse, lineal descendant (including adopted
children), father, mother, brother or sister of the transferor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing restrictions shall not apply to the exercise of
any of the undersigned&#146;s rights to acquire shares of Common Stock or other securities of the Company issued pursuant to any stock option or similar equity incentive or compensation plan approved by the Board of Directors of the Company
(&#147;<B>Equity Incentive Grants</B>&#148;), provided that, in each case, such plan is in effect as of the date of this Lock-Up Agreement (it being understood that any subsequent sale, transfer or disposition of any Company securities issued upon
exercise of such Equity Incentive Grants shall be subject to the restrictions set forth in this Lock-Up Agreement). Furthermore, to the extent the undersigned receives shares of Common Stock as part of an Equity Incentive Grant, the undersigned may
offer, sell, contract to sell, or otherwise dispose of up to the number of such shares of Common Stock necessary to satisfy withholding tax obligations incurred by the undersigned in connection with such Equity Incentive Grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anything contained herein to the contrary notwithstanding, any person to whom shares of Common Stock, securities convertible into or
exercisable or exchangeable for Common Stock or Beneficially Owned Shares are transferred from the undersigned shall be bound by the terms of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, the undersigned hereby waives, from the date hereof until the expiration of the Lock-Up Period, any and all rights, if any, to request or demand registration pursuant to the Securities Act of
1933, as amended, of any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock that are registered in the name of the undersigned or that are Beneficially Owned Shares. In order to enable the aforesaid
covenants to be enforced, the undersigned hereby consents to the placing of legends and/or stop transfer orders with the transfer agent of the Common Stock with respect to any shares of Common Stock, securities convertible into or exercisable or
exchangeable for Common Stock or Beneficially Owned Shares. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned understands that if the Underwriting Agreement does not become effective by
April&nbsp;15, 2012, or if the Offering is terminated prior to payment for and delivery of the Common Stock to be sold thereunder, the undersigned shall be released from all obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this agreement and that
this agreement has been duly executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the
undersigned and shall be binding upon the undersigned and upon the heirs, personal representatives, successors and assigns of the undersigned. </FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signatory]</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d329230dex51.htm
<DESCRIPTION>OPINION OF TROYGOULD PC
<TEXT>
<HTML><HEAD>
<TITLE>Opinion of TroyGould PC</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 5.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">TroyGould PC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1801 Century Park East, 16</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, California 90067 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;5, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">310 North State Street, Suite 208 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lake Oswego, Oregon 97034 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Registration Statement on Form S-3 (Registration No.&nbsp;333-167025)</U> </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This opinion letter is furnished to you in connection with
the above-referenced registration statement (the &#147;<U>Registration Statement</U>&#148;), the base prospectus dated May&nbsp;21, 2010 (the &#147;<U>Base Prospectus</U>&#148;), the preliminary prospectus supplement dated April&nbsp;4, 2012 (the
&#147;<U>Preliminary Prospectus</U>&#148;) and the prospectus supplement dated April&nbsp;5, 2012 (the &#147;<U>Prospectus Supplement</U>&#148; and, collectively with the Base Prospectus and the Preliminary Prospectus, the
&#147;<U>Prospectus</U>&#148;). The Prospectus relates to the offer and sale by Galena Biopharma, Inc. (the &#147;<U>Company</U>&#148;) of up to 9,775,000 of shares (the &#147;<U>Shares</U>&#148;) of the Company&#146;s common stock, par value
$0.0001 per share. The Shares are covered by the Registration Statement. We understand that the Shares are to be offered and sold in the manner described in the Prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have acted as counsel for the Company in connection with the offer and sale of the Shares. For purposes of this opinion letter, we have examined and relied upon the Registration Statement, the
Prospectus and such other documents, records, certificates and other instruments as we have deemed necessary or appropriate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The opinion expressed below is limited to the Delaware General Corporation Law, including the applicable provisions of the Delaware
Constitution, and the reported judicial decisions interpreting those laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based upon and subject to the foregoing, we are of
the opinion that the Shares, when sold and paid for as described in the Prospectus, will be duly authorized, validly issued, fully paid and non-assessable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We hereby consent to your filing this opinion as an exhibit to a Current Report on Form 8-K to be incorporated by reference in the Registration Statement and to the use of our name under the caption
&#147;Legal Matters&#148; in the Prospectus Supplement. Our consent shall not be deemed an admission that we are experts whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the
Securities and Exchange Commission thereunder. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April 5, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page
 2
 of 2 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This opinion may be used only in connection with the offer and sale of the Shares while
the Registration Statement remains effective. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very truly yours,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">/S/ TROYGOULD PC</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d329230dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g329230galena_logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Galena Biopharma Announces Public Offering of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake
Oswego, Oregon, April&nbsp;4, 2012</B>&#151; Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, announced today that it
intends to offer shares of its common stock in an underwritten public offering. Roth Capital Partners, LLC is acting as the sole book-running manager for the offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The company intends to use the net proceeds of the offering for working capital and other general corporate purposes, including the Phase 3 NeuVax&#153; (E75) PRESENT (<U>P</U>revention of
<U>R</U>ecurrence in <U>E</U>arly-<U>S</U>tage, Node-Positive Breast Cancer with Low to Intermediate HER2 <U>E</U>xpression with <U>N</U>euVax <U>T</U>reatment) clinical trial, Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a
planned Phase 2 trial of NeuVax in combination with Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (trastuzumab; Genentech/Roche). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares described above are being offered by the Company pursuant to a shelf registration statement on Form S-3, including a base prospectus,
previously filed and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement related to the offering has been filed with the SEC. Electronic copies of the preliminary prospectus supplement and the base
prospectus relating to the offering may be obtained from Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, (800)&nbsp;678-9147 or e-mail: <U>rothecm@roth.com</U> or by accessing the SEC&#146;s website at www.sec.gov.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Galena Biopharma, Inc., nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Galena Biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena
Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information, please visit us at
www.galenabiopharma.com. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed public offering and the
intended use of proceeds from the offering and statements about plans for the development of our product candidates. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be
completed or as to the actual size or terms of the offering. These forward-looking statements also are subject to risks, uncertainties and assumptions relating to the development of our product candidates, including those detailed from time to time
in our filings with the SEC, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. Our actual results may differ materially from those contemplated by these
forward-looking statements. We do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Madeline Hatton </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Toll free: +1 (855)&nbsp;855-GALE (4253), ext. 109 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>info@galenabiopharma.com</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Remy Bernarda </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IR Sense, LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">+1 (503)&nbsp;400-6995 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">remy@irsense.com </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d329230dex992.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.2 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g329230galena_logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I></I><B>Galena Biopharma Announces Pricing of Public Offering of Common Stock </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lake Oswego, Oregon, April&nbsp;5, 2012</B>&#151; Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted
oncology treatments addressing major unmet medical needs to advance cancer care, announced today the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a public offering price of $1.50 per share. The company has
also granted to the underwriters a 30-day option to purchase up to an additional 1,275,000 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the
company expects to receive net proceeds of approximately $11,600,000, assuming no exercise of the overallotment option. The offering is expected to close on April 11, 2012, subject to customary closing conditions. Roth Capital Partners, LLC is
acting as the sole book-running manager for the offering. Cantor Fitzgerald &amp; Co. and Rodman &amp; Renshaw, LLC are acting as co-managers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The company intends to use the net proceeds of the offering for working capital and other general corporate purposes, including the Phase 3 NeuVax<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (E75) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial,
Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a planned Phase 2 trial of NeuVax in combination with
Herceptin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (trastuzumab; Genentech/Roche). The shares described above are being offered by the company pursuant
to a shelf registration statement on Form S-3, including a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (SEC. A prospectus supplement related to the offering will be filed with the SEC and will
be available on the SEC&#146;s website at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and the base prospectus relating to the offering may be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport
Beach, CA 92660, (800) 678-9147 or email: <U>rothecm@roth.com</U> or by accessing the SEC&#146;s website, <U>www.sec.gov</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press
release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Galena Biopharma
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that
address major unmet medical needs to advance cancer care. For more information, please visit us at www.galenabiopharma.com. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed public offering and
the intended use of proceeds from the offering and statements about plans for the development of our product candidates. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be
completed or as to the actual size or terms of the offering. These forward-looking statements also are subject to risks, uncertainties and assumptions relating to the development of our product candidates, including those detailed from time to time
in our filings with the SEC, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. Our actual results may differ materially from those contemplated by these
forward-looking statements. We do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Madeline Hatton </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Toll free: +1 (855) 855-GALE (4253), ext. 109 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>info@galenabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remy Bernarda </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IR Sense, LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1 (503) 400-6995 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">remy@irsense.com </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g329230galena_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g329230galena_logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`50!U`P$1``(1`0,1`?_$`*8```$%``,!`0$`````
M```````&!P@)"@(#!00!"P$!``$$`P$```````````````8!!0<(`@,$"1``
M``8!`P(%`@4#`P4``````0(#!`4&!P`1"!()(1,4%18Q%T%1(B,8<3(*85(9
M@9&A)"41``$"!0,"!0,!!@8"`P````$1`@`2`P0%(3$&01-1(A05!V$R%G&!
MH4(C,PCPD<'A4F(D)8)35/_:``P#`0`"$0,1`#\`W\:0@TA!I"#2$&D(ZEA`
M"#O_`./$1\!\`#\1'7%U1E(3/VCKJ@NID#>(^<B\_5WCMC&<R#*0LK:7K1NL
MC`U6%49,G4]-%1$Z#1[/3#EC7*E$("('>R<HY;,63?J.<PCTD-=L%AKC.W;:
M%JQQ#GA2`26@E%0:D^`&YBV9'+66(QYJW+VL(!12FOU78#K%)-[[_%)C:#!1
M-'QW7K;GAS&"6YI5^WJV;!])FCF6*=E#7XD9!2F1BM4^@#JL&;=F*O61-PH4
M`,;9;AG]L&4SEX;GD%<V?&G%091WZ@79S%6FHZD'Q2-1_E;^[K#\.MGV7$[;
MW'D[007:]EA3<.&CM43S)^L2#[9O+/,F=[.U/E^U(V*;RLRR=>XN-;MFT?%5
MBEXLD*136#.`BVJ9?3-7]FN#KK7.=5146HE,83%':-_.G"N/<'OV8;CS`VSM
MK>DKEF<YU28N+CNI:UI`T18O?]IO.^<?(W&+[F/+ZW<JWE[6IM$LH8VB0C&A
M=F]PC]D79D`0/L`^&XB;^@_V[?\`7?6NE*G4ITFL/VA?]HVU>7.+7-_II'T:
M[8I!I"#2$&D(-(0:0@TA!I"#2$(VY7FLX_@Y*TW.Q5^JUJ)2.M(3=CE&L/&M
M$TRB<YE7KU=)'J`@#L0/UF'P`!'PUZ;&TO,E<"RQ]O<5[UQ1K*;9BX>(3IKU
MBW9;,XCC^/?E,[<T;2PI^9U2HX-:&C4C74N14`W\(J5Y1]ZOC5Q\QVXO$0WD
M,B>[I2C/&#9DM[$CEBP,E/1G^'IRB*4J]I4,\.`2EA.W2C$>D4FRCI<WEAE_
MCOPAR;*WS<=DJEO1N]'5*8(<^C2.Q>29)SJC`XN&[@!O@_*_W!\<I8ZME<1;
M7%;$!6TJ[VRLKO`U%(?>@T))`!"@*8RZ<H<ZYL[LU+0GC72;BL]8T;RS\>,D
M1895GAW,M";'>3*<[B>M.Y$[)',U)CS;/8UV+E6?8HE79"5RF9`^R?'.'VOQ
M%D&UGT*=Y@*NCK@M+JM)Y``G+?+)-LZ5&H`[1#&%[;Y6L_EPUN.7[QC>02N[
M5,F2G5:`4;YR3.X:("%)TBK#&5I5:*"5X"Z"C99=NY;JMU6JK=PR.9-1%PU5
M(F=!T1<AB*$,0ABF)L(;AK8#&W]JR?)4JRN+0A*=L@A2H1`5V1(T^YYQ:XIU
MJV,(=3O:9*TSO,'`2@ZN(1=%C7;VF7;EKSVD\='%4D5@3MY8<I#\RB:9&J>2
M<PW`N;K1#%7`"$/,&;31!.B`F<&(S.<2]!!$-&?F6O:7^)N;YA?4NZ^9K@G=
M*-'R4G`A?*X%03Y?!-H^A?\`;MBGX7C^.P[2+<-QM*X?3*!IKW+0ZJW756EH
M"*OB3&H0H?KZM_J&VP?3P_/?QUK./,\O#E"`)X1L_P#P@;2QVZYP@TA!I"#2
M$&D(-(0:0@TA!I",TG>AXB6\<SX6YR2\GD+,?%O&5PI2'*7CDYLLVO6JQCF.
ME&J4MDNE5^-71*BP(Q7,I84BE,J!$07*<J9EP+L#\0\[M<1C,CQNBRVH<AN;
M9S;>[<P%[7%KP&-*%'J06G3ZD(L8&^5_CRIRN_L<C4;6NL73N&MKVA>E-[)F
MF<B8:(JC]VL4X<R<-<(<@9^R)*9!S%RIQ+>V<R,2PD96NTG/&)6M0;(D<4MG
M1F,(:A3]>QX-9>M5HIFR;`W0:+%Z>I3K.IG[B5MSO&\<M,GB:6.RK22][#-2
MN"]Q,W<J.;*[]#4".!4+K&IW,/D'XLO>0W'#<W;Y+$W5D^1AIRNMFME$K@QK
MU4.)4BF21X[0Q5'XWT>+FHU_ACFOQNN4E%O&TI#H25RG\`WN.?L52K,7#9GD
MZ,AF"<D@L0#$]+)+`0P>!]3MO.'XVF;;FF%O;3&W&CBP4;BF%W!%*I5>A\`T
MF,9Y?XDR6>K,RWQWG;"^R%-X?3!-6E6!&K1_,ITVJH`^Y/$IK$K+IVZLH<H[
MO2<BU_'(5G-+^W4YKFUM57%=D\79JJ3B9CFLSEVJ6&HR,G4H?*$=$JJ+SL:"
MR+>;1(9ZUZ7'G)FQM=<TXSPIMWV+]MWQ>YIO+6EM5K[1TR,8YM1C*A;K*T@.
M(V.B&,I<=XWR_GHL\/S#%5;#GU"X:'UG&FYETT-<7O#Z;WTP1*I4@'HNT0EY
MS\D+'C'EM/U#"=LEJ18,69UM^4+1>*Z\=Q+Z<SDZ$("/3C71P14DZAA^@L&=
M4BTC%.T6*F_5`HD<^//XZXWC<O@W7N;91K/NJ`IMHDM=*Q-"B_QJNNNRH1&1
M_F#-7>!=1MN.UWTV6SRYM9C7`5$(1JR_P@)JF_@HC7!VJNZ]5N:=:C\<Y86B
M:;R3@XHIGK%$XM:_E%BT2`JMHIY5!!)O(BF0%'L7N91`QA.CUHCN77?Y1^'[
M_A-=^4QK'5L$]VK@I-$DZ-=UE\';#0$K&3?AOYZQG/)>/YZK2M>3TP0QCBAK
M@#S.!^U1X$@GH(NH(ND<-R*%,&P#N'Y"`"&WY[@.L*$(Z4_=&QG<8I"ZC_&G
MC^R.T/$-_P`]4CF""%&T&D5@TA!I"#2$&D(-(0:0CRY&/92C-_&2C1M(QLBT
M<L'\>]23<M'C)\D=NZ9NFZQ3I+M72"AB'(8!*8AA`0VU6D]XK3M5KVHA'TZ_
MJ(Z*C!(XU-0=OU_WC)YWA^VY.P5FQ)=N/%;C&M`=TX]!N+JT6N"K%7H`4]01
MICB:M=HD(UBPARUEV6*:E.HHX,2/02("A@UN)\$?+5G;X2[P&?=4?7:^>BU@
M+G52]`6(J_<ITTUZ:F-`/[E_A.O<\OMN6\<8&6M:F&UZBRLIO82XN>>H+2$5
M=C%&"G&GB_5'('S%FZ7S'))'$RF/^/K`T75$UB&,51M*9EO3("/$R'``-[+!
MNRGW-T+@``8<\6];G'(:G:Q5DS%V>_>K!7)_R%-H_:CG`Z(0#&"*>?\`C[@3
M"ZO7?F<X&GR6ODIM<FSGF51T*`Z>,3OX8\A:?QSM=@O&%,;TO#6/\44F8O=M
M;0'K[):+>BB[CJO68FYY!M#AY/RS>1MMF9$5;-`8-UQ*!?*Z0$-0?Y#^.L/6
MP5*C=5GY3.WEQ4I=YYD:"KWDM;J$\FNA/4$$1-?ACYF^0_D#Y/L[=C:6-X?8
MT^X^DT!Q("4]72@E9]%B$&?^;G)VD<EL]XJOECI6;:=4,T9,K\=6N0F,\>Y3
M8,XA&UR@,&L=-6.!&U,"H1RB9$?(DDS)D*`%'8`U3A_`,#7Q%E<A;7).M:;B
M^C<5*517-"F5LK"%^TEQ/Z1F?Y8YCE\%<U;:VH-K8JG=5&M%6@RHQQ:=4)F=
MKHOETZ&)X\0J*XY'R4#8Z!V_[A6[)'23"48Y1XRW6]8G@H&3;JIG3D6:&1%K
M90TU`$@',+=R4FP"7HZ1$->OE-\WB-A6L\ER.SKV3Z;AV+RE3JUGAP(05`>X
M4\5/UC76TP_(^=YIF1X]PNX%ZRJTB\MJ[Z+:9:5F[0:&;]-/HL;1L,-+S'XR
MJ[7)*SQU<VL8DE-NI,T,K+J+)!Y::DNXKIO8W<L9`I?/7:@1)53<P$)OTAH#
MEJN-K92O7Q8EM"XZ!4VV:NJ>`Z;1]0N*4\O1XS:4N05N[EJ5,3NJ`%S$Z%%4
M@=>L.Z0=R$$-]A*40W^OB`?7_75M")IM$H!!"@J#U\?K'+58K!I"#2$&D(-(
M0:0@TA'`4R&WW*4=_KN'UV^F^JJ=_"#@'@!VH!B+7-'$U:S/QFR_0K-0T<B1
MTC2YM^2K$.FWE7S^%9*RK(]:D%"F",MB*K7>,<?VIO?+`X"F)]7OC&8N,)R&
MSN+6HZD\U0)FDA/U3^$Z+$7YAQ;'\LXW=82^8QU.JPH2%E<0DP\"FBQ_.+SY
M6)K"=IB6A99>S4&[P+>[8COOH'44SOE#DE5VC=X9H[2*>/L5?>HJ1LW'B(*1
MLJV42\2]!C?3;AG/6\PQ;'-NG-J6[)'LG7S`(0?'?0]0ACY3\P^);KB&6K63
MVDV;GDM?+H?\;?YQ(3COCJ\9\PN\Q9CWSE[SROY*X3X\U1P1,ZQ(^JT))YF?
M)]D6$@@!HRN`UA5W6^Y.E,2GVZ@UC[Y)S]"AD6'+,:<+8V=2JT$$CNN1K7CI
M.CGA-_-&9_[?."5J5O>WMO2-.^K5FL#P$=+,KF@[H2UI/10(VWX[[47!FFY/
ML6<9;!U:R/F.X3I[58+ODA-Q<DQLBS=NC(/X"NS"CFN5Y%RX1,H4B37S"F./
MZAUI)7^2>7W.-9AFW]Q2Q5)G;;2:XM:&MT&B]1U"+&^;N&<8J7'K;RPMJN0F
MF-1S`YY)U52/'7_6+&V,;'QC1O'1K)G'1S1,J+2/8MD6;)LD0-BI-VK<B:"*
M90^A2E``U`ZU)UQ5[EPXO:>AUUZ$KX1):3&4&246AC1X``?NC[`(0/H4H?T`
M`UW#02C8003%W\1W^L<M(K!I"#2$&D(-(0:0@TA!I"#2$=2J?F``#MM^(&`1
M`0_H`A]-5!(!+=')H?"!#7-+'!6F*T.Y;VXL<\_./C['CEO$57)U+)(6'"%]
M08HMQJ=M,V-U13X&X%%:IVD2@A)-P#80$JY`\U,HC-N`<UR?#<VR\=4=4L'O
M`JL!16[$]=1N$&NQ^D.YAPO"<IQOI;BBT5&"9KM-QJ!TT7>(6]F+MO6OC?C;
M%E_SI6?CF5*57\L,HZMNU4G:L);LG7Q1K=+$;RS&2!TM1:/!QS)<@]0LE5A`
M0!40U+OEWY`')+VO;XZK-8UC33?1M-I#1X;N))'@`8M7QSQBEQW&-MW,`JMJ
M/>J(LSB4_P#B"G[XT!$)T@(>'U';8-@`/P#;Z!MK"Q87$EQ\RZ?ITC(P)ZZQ
MSV'\]4:QX*ERMBND?NNV*0:0@TA!I"#2$,]=>0V`<:S(UW(V<L/4"P`V0>#!
M77)E+JLR#-R'4V=#&3LVP>@V<%\2'Z.DX?01TA"23YA<2EU4D6_*;CDJJLHD
M@BDGF[&:BBJZZI$44DR$LQC'5664*0I0W$QC``>(AI")&E$!*4P"`@(`("`A
ML.X>`@(>`[Z0A&J9'QXC=F^-%KY3$LCNXH\ZTQ^I:(,EV=0:0*"I,MZJ9\$Z
MM%)@D;J<%0%$.D=S>`Z0A9@("&X#N`_00\0TA"6J]XI5X),J4NX5:WIUV<>U
MFP'J]@B;`2"LD9Y?N5?F31+MV6,G(_SB>>T7Z%TNH.H@;AI"%.)2^([!N.VX
M[?7;Z?\`;5#L5VA"(L60L?4IT@VM]XI]4=O$A5;(66SPL"LY0*;H%5NA*OFJ
MBR13!L)B`(;A]==5(TR$:"/U7_6.+GH96C2/$3SGA)4Y$T\Q8L4455312(GD
M*I'.HJLH5)%,A2RXB=150P%*4/$QA``\==T<D2%].S\%5H:2L=FFHFNUZ%9K
M2,Q/3LDSB(:)CVQ!4</Y*4D%F[%@S03#J.JJH0A0\1$`TA'U,9&/E&+.4C'S
M.1C)%HW?Q\BQ<HNV+]B[2(X:O6;MN=1NZ:.4%"G34(8Q#D,`@(@(#I"/&5NE
M.0MC6A+6RM(WE]#KV%E3%9V+3MCR`;.`:.9QK73N@F'$.W=&!([DB(HD4'I$
MP#X:0A2"(%#<P@`>'B(@`>([!XC^8CI"$=7LBX^MTW9JU5+U3;/8Z4[287*`
MKUGA)J;J3Y<RQ465FBHU\Y?0+M8S=0"INDTCF$AM@_2.R$++2$9-N"O#'BCS
M-[H_?<FN67'S%?(:5Q[RHPS6Z-(Y:JL=<'-3K[C&,L56%@599)<(V-5+&M]T
MDP`O[)?RTA'E<B<K=EC@;<+A=[KV0<Q5NIX#OT2R3Y(P_!""C\2)69C/1K6O
MV*J7B<DHM!U'K659!-B]%$A%UP)Y?5N72$:;<M\@L9X1X_W?DGDR:+6,5X^Q
MI(94LTS("D@JSK<;"$G!2*B*W2>5=D.1NW0*<QE72A$R[B<NZ$8),FS["*HL
MUWP\F<G\2XB[MKG-53YD81XG7[,4%6+6WX"-XIQ5ZAQC>420E1?&?9.PZ^/,
M(D],55V51(I0\QP<=(1O`XF\F\9<Q..6'.2V()(DE0,QTB'N$'^LAW44J\0Z
M)BMRA"[>GFZO,HN(]ZD(`*;EL<-M@TA%(?\`C@ID)6.[`)`*0H]X#ER3H*0I
M"E\HU/('3T_[OK_72$:1Q^@_T_'2$8NLOX@XVYY[TO=_LO+SB)>.?$+QXP;P
MF;8@PA2JS+Y#O,4M=X%NVFRX_JK>Q5R/;-U%EA>2"JBR22:1%%!'J,('0B8G
M"GAKVO\`*N?*PVKW82SOQ7GZ2F;(4%F'D+A5"FT.!GJL]8.H5LV>*90L@25C
M</SE4:-O1+$W1,<^Q0WTA%HO>H,*?:6[AQR@43)\3LP'`#!N013JKTP`(?38
M=M(12GPZR7R4[,_&;C!DV_OL@\G.TQE_">&[O89[RGENS5V\K3?J=`3$ZX>H
MMRK2MZXN.9N356`R93.JV4YB@3R2E!9")0JWZCY5_P`C3B)D[&UIA+U0;MVD
M,J6"H7"KOVLO7K'!R.9(ETSDXB2:JK(N6RR:@!L!@.0VY3;"`AI"++>Z?SA9
M\!N'M^S)$QWRC,4^XCL4<<,=($]3*Y'Y`9%4-`XWK,;'D(HN_30EE_7O"IE$
M0:,U/$!$-(1D(Q7>N-_9.S=PVY85WFYB#.V7\L3DQ@WO,X[@LT5V\W5_=\LV
MU_<CY>85B/G%W7FX$O;IQ'N_+1W%JTW'Q<*B5"-^'RRO?'/F'N\;\3]F"R?)
M?6M_9!KGMHS`SWN77Z7VH(O]_P`[JZ/*'JWVTA%`D[VU>Y5@[F%S*Y%<`.8'
M&7'%/YKWNFY2R'2^0."K1D.?@K94JRK64VL#,P%DC6?L:Y7*ZP`=,%=U`*.X
M%`10AJN5/;&[SO/3#$WQ=Y:\[>%+OCY?YZD/<C(XKXS7JOY"4BZ9<H*Y()U6
M6?W%9DSD57\&D4!5*)#%,)1\##I"+'>XCP!NW.VD<;^.9\EQ5*XG5'*5/NW*
M6E*,I)Q=LY4;&"#"1IF*XV09F3C8VO2]E8$<3!W)A%5-%+RP$2[:0B:$_P`5
MN,-KE33=KXXX,L\XJA&LS3%DQ11)Z5.TB&#:*BFBDC*0;M\+2,CFJ39N03"F
MBD0A2@!0`-(1!_MN]OF^]O"]<L*-5\DU>P\,<LY=D<T<<<0(14PVMO'Z:N9C
MO,C4I*0754@W5!?RI4UXU%L"9FXD_47<YS&0BO'`_:][PG#FW<I0XB\U^&%7
MQAR1Y49?Y/+0.4N/E]NMHBIG*,PDN$>M,-;)%H`DRAX]HD)"%%,52&.7;K$-
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M5&94/#RA5RK0\T#%01;N"G`45.@X#XZ0BIOC+V0Z+PU[EC?F1QZR,^KW'D,-
MY5Q_&<7IH)>7B<4V?)MGA;3+J8<D5'"K6NXZDY.,5=*PZA=FKQ40;G\L>@J$
M2?S1P'N/)#N*<<^5.8\@5>;XX\0Z7.RV",`-8N6-)+\D;7_Z#_,UX?.7(P<B
M6K5\I$(-NFAYC5P05C#N8=T(?;+O;NX39IQIDC&ENXP8+0B<H5:SUJPRT-BB
MA1=G;_*HYTR?S<58&D`C),;$W5="X1>$4!8KDA5.K?2$5IAVRN>/_$0?MC#S
M#H`6D)!/$1.1'QFV_(C<.1?JF4HXM_5>I#*!:J!($'W7Z(8H1#^\.O2$3YN'
M<:Q!2IC)3&2I&4GL/B7("F-KI:HM#'JC%O96KZ$CGGM5=>Y$:7N98-UY]O\`
MK:Q*AEB]8ID/T^,SH<%S%>WM[@U+9C;FV->F'O<'&F)]T80"9'("4V4A8AE?
MG.(HW56T%*\>^C7%%Q92!;.9=C.%;YAJGCI$Q,HY)KV(\:WS*MK2DCU;'M4G
M+K/EBFP.Y0T-7HU:3D?;V9UVY7+WTS<WEIBH0#FV`1#43M[>K=7;;*D/YSW!
MH793]?")55NZ-&T-[4)%%K5/BGZ>,*`MJB@J7S-07",*6N!:%#&2,9RG%^UA
M+F$44S&,9<C/ZD`1$3!L&JFVJB\-CIWQ4D^DRR[^"]8KZFEZ07NO8-.?ZRI-
MMXI$.J]SIJLQ"XRN;_"&?JKC?+\[0(&F9%L-<HI:RX7RB_8QE#?/T(K($K8F
M,=.NI1N!5#,C&2!8OF%+N.TJK<)R%%]U1-UCS=V;*CJE,5B7I2*/#1(`2#T4
M1%Z/-<?6?;2VN0%O=N8VG5-%*2U`K5?/IH-=#$C<VYAJ^!L6W#+ER:S;^MTM
MBS>R+&O,V[^<>B_E&$,R:QS5V\CFJKAQ(221/W%TB%`1,8P``ZC&-LJ^5R+,
M9:A+A[D!=HU=]]=-/")#D,C;8W'/R=S-Z:FU2@5R;;*-?VPWN-.4$%?\J.\.
MRV.,FXTOJ5!6R0QCKTTIYV4Q4VD^TK;UW&R%/N-L;@Y9RK]$ITE_(.)5.HO4
M`#M=<AQR]QV)&:?4MZMD:YI?RWES@]K`\J"T:2D)KN=HM^.Y'C\I>NQ]JVMZ
MAM%M4S-02.<6#53JH.G[X6%GY`XPIN5X;$-MGV];LDY0);),:_G7L9#5U:#A
MK#%5AZS+*23]J569]?,(G*V(0XBB!CB(`78>BA@<I<X<YVWIE]@+@42BEP>6
M=S[0-I>J[Z1W5\]CK;(#&5WEMT:)JZH!*'R;D[S=/"/2Q'FFC9J:7>2H3IS(
M1M&R)9,9R<D8&YV$A8*J#+W1S!NVKIVWD84QI`@(N"F`%#%,'2'3KSY+%7N(
MJTJ-\V2I6H-K-&NC'A1,H!#O$1ZL?D[/)MJ/LW3-IU"PG3[AH40E1]825_Y.
MXOQQEJ@X<LA[`%EOIV)4I9A#JNJG4UYQV[C*:A>)XJZ:-=6O<S'.&,.50I_5
MND#$'H_2)O19X&_OL75R]#M^EH[@N1[M%,C4\THU=KHHWCQ7/(<=:9.GB:Y>
M+JKMIY1J@F*Z+TTUAV[S=(;'],M]ZL'JP@J569RV3(LT`<.S15>BW4Q(>C0%
M1/U#GTC,_07J*!C@`;AKP65I4O[^AC:!;ZJXJ-8T$H%<0T%VZ!3J==(NEW=4
M;*QJY"L?_&I4W/<1J96-+B@ZE!I$8\=<SJK>[GB>FR6+<N8^<9P@)NP8PE[G
M&TP8:PMJ]66UPD6IU*Q=+'(13TM;=E<$*Z02*80,F)@4#I&_77$[^UM+F\=6
MM'LM"T5&LJ$O\S^V)06B9';H=!K%AMN6XB[O+:QH]TU[LD4_*$\K.X9C-IY8
M='-?(S&/'U7&:F3'DI$QV4K\TQS#3C:-7>P\--O8>5F6S^VO$C@6`K?E1)DE
M7ZH"@@LJGYHD(8QRV_$8+(YMMV['M#O1T.[4!*$MF8WR!#,Y7C331?"+AE,U
M88=]NR^+F^IK=IA`4!P:YWF*A`C#KKJGC!7N1V,[9GBZ<=Z\]DI._P"/*9$7
M6VKH1ZGQJ,;3<B,>TA"3O7Z=Y96_[:SMFF!A:H.$14,4R@$U6YP.3L\)0Y!<
MLDQUQ4<RF2?,XLW,O_'HIW/1-8Z[?/XR[S#\);O+[YE+N%/M`4!%7?4:)'9G
MG/U+X]4]O<;DTLTP5]*MX.(K-,@EK-:YUZ=N[DGPPT`V62<O48."C74B^.`@
M#=BU54'<0*4W5A,/>Y^]-C8R![0I=4,C!JFKRH&I`_4QRS6<L,!9MO+\OD<4
M#6"9YT71JB%]]QJ9\"^Y_P`@C/@7Q3YO\K]6C[+\5]I][]\];U>7[=[6'G=?
M^W\-_#7@[%?U_MLCO6]R25-55/\`)>L7#U5'T/N*_P#B]N=>J(J?K](SX9H8
M<=CVCE8O,6K(*$%_)Z6/DF+CJ!PX=Y/^6A/T3W1OB^=MV2V6=1KIWWI/0K-8
M[UI4A6].D80+OEVU=R$6F(]<RW+_`&=W:\]R&=O^>A?*PTP[[M"2")9B%"8R
MN6V!NLAV'U@?<6SRLIGS?R=BYX=X*0%W0$1=;RX+3S\5>1!+ZM9&]&-AG(9;
M>O4VS!Y:T:Z-8D`EU:ZTF';"+<S9&/6+=-PNDB9;8#G*&XZQ9C/7>^6QI23=
MP)NBKHI&J*G3;:)GD/1^QUU+Y.UYM`NXZ+O^W]8</:`##.SDTD:J_;#98_EH
MEF!K_P`1_?-Y::AVQ9(8W<>DIQ("O@`[>.N%3UOY!5^V?U/U2:?H=T7Z*G18
M]5'TWLE'>3TH3Q3M]>FW[XIRI<?()X8X>+6^W<H7G&(MXXLFQ;'S>.N)L:*N
M]BK?V21MTQ3LI2MZ;QA9,8[W!1NQ4<BF!NH@")MLI73ZGY)G?Y>/]]]-==[^
M9<(!,.YVUI(7+]JRM/TC&UFQOL^%/<O_`&;OV_;!ITD)E<DQ%50WQ0$[18US
MR)C,_$K-!<S.+`UQ<,-`?,UZFSA7TVG$A<JV(>D:6%]'0JK8SH$P=>>L0H-!
M5$-S`4#8]P'N'O-M[:`;R<R*4,R%-@?K&1<[[=[#<>NTM9?,FNB]-HY\=_X4
M?++3_&G[$?-/8V?RO[7_`!SY'\<]>/H_>/;O_J^U!)_3J_8\[;?]>VNS)_E7
MH?\`W7=]'ZA\B_;/(V;Z3(B_1(Z<3^/>X_\`I)?4^E9-+_\`7.Z7?5)E1=8;
M'-Y.*G\P:&?/R]5"Q!QNO!:TURNTQ\.*C0(Y,IPS*Z3^XO0>DOI94$"I)-VQ
MD18"J8Z@&`I1N>._*_Q1_ML_MGN+5DFG[G8T"-Z2IJO@$ZQ:,G^.?E+?<_ZW
MMSDF267O^)ZJNB?MA9<(R87+6LY_8-PLO23\FLK'=`W9U9I5T+&):_[TWQX-
M/?/(AW14U0)Z)8_DN#J"KUI%V#?R\F]W]9;^^KZKT-*6:99)1+-,%7>9>L>S
MC'L_IKOVE9?4/^U-YCM]/#:(`<AT^%);/RO+G5WRH4R\>WP(V%>OQV2$7+<3
MIQW\=D\?M:!*.,;O(UM,BF%3/-+(.%I<%A=%2W,`2_#GEG:Q9QHL!A.V^4.+
M"PE&][N%P#QI_4E!";=8CV=&&6Z%^:_NJM0@"8#S22A4(_4A?I%IN2R-`XLY
M"3OKJX&9_8FTDN+P&%=)?13^W[HMB<IQB$BI4PN/D^<8$$W?H/7=105\K]>H
M#A3=CE5`T1;&M[A3[8)<*?\`4;+JCG%B_P#4%(EF7%M^-7`O"_T?HGSE!-]I
M7147QU_;%:W$]+@</)S$)N*;\"Y`1XXP_P`V3B8G':E6D:V-;CBPPRZ\G-)S
M,-EHC7J/+!3$WZ9D1$DN)4P;'&9\F_-!QJ[_`"`4CB?4:*7@?U.D@*T]Y>ZF
MJ)YI8C>#_$/R"R]J7U_;<FR?T?J5F3>7Z]%B=_*8N'1GL`#FA=VG7B7G(@HI
MNVL,M3EV0X-R4%L3R(K+O$#M*J6GB^-UMB+*&>`B42@41,$5XW[UZ&]]D_\`
MSLGE7[._3D1$7S2HI&FOTB]\F]KFLO=)>WZQR+LO:K+]41=M=H8OB*7BQ]VJ
MJ?CFO=_3?QE?%:M9IJ\]N]J^\D@,\O<WUJ>?<`<MC;.LKY*1;]0,?),*@_ME
MU<.1?E'ME;WW6U]6V15`#NV5D16ELLJHB%-]8MV$_&SFK?VF47GHW32ZDMF8
MD^R%=MUUVC[>7!./X<A,4J<@W&=S&''5R+AYKCYI="TY.PE=)#D5=)_BQ\>[
M+7M2H&0*HD];$CB0A5C(*'.9R4G+C/O7M=48$49NZSN%Q;,B^10\22S;:K-'
M7RD8'W>D>0&KVNTZ0-'E_P"VH*S)N"$3K#$>3QZ_XX-_<>2W\+/N;YP%]E;_
M`##^/OW%V&.$_O\`\\^P/J]A![T_*?C6X>E\KQU=ESOYMM9>_P#8\2G>DWVE
>[LO3^G-_$L6U,+^'[WWL_J/!LTGAO_27K]R](__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
